

INDEX TO VOLUME 30

Author Index

- Abal, A. T., S201
 Abbott, M., 949
 Abele-Horn, M., 405
 Abi-Hanna, P., 630
 Aboulafia, D. M., 826
 Acar, J., 454
 Acosta, E. P., S151
 Active Bacterial Core Surveillance Team, 212
 Adult and Adolescent Spectrum of HIV Disease Project Group, 241, 955
 Agbemazdo, B., 229
 Agnew, K., 901
 Aguero-Rosenfeld, M. E., 545
 AIDS Cooperative Treatment Groups, 47
 Åkesson, A., 585
 Akiti, T., 300
 Alanen, A., 363
 Alangaden, G., 984
 Alcantara, R., 400
 Aliaga, L., 461
 Allen, S. D., 141
 Almela, M., 368
 Alonso-Pulpón, L., 603
 Alvarez, A., 400
 Alzieu, M., 209
 Amir, J., 500
 Amoudy, H. A., S201
 Ampel, N. M., 658
 Amstey, M. S., 237
 Andersen, P., S201
 Anderson, P. L., S151
 Ando, Y., 185
 Andrade, R. J., 400
 Angarano, G., 831
 Anunnatsiri, S., 29
 Aoki, F. Y., 549
 Arbeit, R. D., S309
 Arduino, M. J., 35
 Areff, D., 433
 Armenian, H. K., 946
 Arribas, J. R., 915
 Arya, S. C., 988
 Asch, S. M., S85, 293
 Ascioğlu, S., 41
 Asensio, A., 55
 Ashkin, D., 779
 Ashley, R. L., 839
 Asnis, D. S., 413
 Atkins, B., 942
 Avšič-Županc, T., 987
 Baboo, K. S., S309
 Baddour, L. M., 87
 Baden, L., 609
 Baker, C. J., 276, 282
 Balotta, C., 962
 Baquero, F., 55
 Baraldès, M. A., 615
 Baran, J., Jr., 396
 Barbour, J. D., 504
 Barlam, T. F., 622
 Barr, D., S85
 Barreiros, G., 300
 Barrera, A., 461
 Barrio, J. L., 615
 Barrio, V. R., 408
 Bartlett, M. S., 141
 Bartoloni, A., 210
 Bartt, R., 229
 Bashore, T., 633
 Bass, C. R., 387
 Bassetti, D., 947
 Bassetti, M., 947
 Baumgarten, K., 639
 Baxter, R., 406
 Beavis, K. G., 384
 Belmaker, I., 319
 Belshe, R. B., S217
 Beni, S., 825
 Benilevi, D., 982
 Benito, L. M., 976
 Bennett, J. E., 696
 Berenguer, J., 182
 Bergström, T., 529
 Bernard, E., 201
 Bernardin, G., 201
 Bertino, J. S., Jr., 440
 Bertolli, J., 55
 Bettelheim, K. A., 984
 Bhargava, A., 954
 Bianchine, P. J., 35
 Biasoli, L., 300
 Bilenko, N., 419
 Binswanger, I. A., 579
 Bjerke, R., 582
 Bjerre, A., 643
 Blanchard, J. F., 946
 Blanco, M., 976
 Blower, S. M., S316
 Bluthenthal, R. N., 579
 Blythe, D., 61
 Bodey, G. P., 851
 Böhn, I., 606
 Boissy, C., 201
 Bolte, E. R., 213
 Boscia, D., 831
 Bossi, P., 227
 Bossolasco, S., 95
 Böttger, E., 210
 Boutin, P., 540
 Bouza, E., 306
 Boylan, A., 569
 Bozzette, S. A., S85
 Bradsher, R., 688
 Bradsher, R. W., Jr., 679
 Brambilla, A. M., 95
 Brandtæg, P., 643
 Brankovic, L. E., 195
 Breiman, R. F., 71, S199, 520
 Brennan, M. J., S247
 Bricaire, F., 227
 Brown, A. E., 625, 819
 Brown, B. A., 288
 Brown, G. H., 440
 Brown, J. W., III, 605
 Brown, K. E., 569
 Brown, R. M., S217
 Brown, T. L., 893
 Bruckner, D. A., 195, 790
 Brundage, R. C., S151
 Bruneel, F., 940
 Brunham, R. C., 946
 Bryant, J., 100, 122
 Bryant, R. E., 349
 Bucher, H. C., 602
 Buck, G., 191
 Burroughs, M., 857
 Busch, D. F., 815
 Bustamante, B., 65
 Busuttill, R. W., 790
 Bwayo, J. J., 486
 Byl, B., 838
 Cabellos, C., 239
 Cadrobbi, P., 619
 Cairns, L., 61
 Camargo, R., 400
 Campbell, G. D., Jr., 679
 Cantón, R., 55
 Capiluppi, B., 962
 Carbonara, S., 831
 Carbonaro, C., 545
 Carmoi, T., 840
 Carneskog, J., 342
 Carr, A., S135
 Carrette, P., 840
 Carson, L. A., 35
 Carter, L. G., 893
 Cartoni, D., 825
 Casari, S., 95
 Casassus, P., 41
 Casellas, J. M., 473
 Castro, S. D., 825
 Catanzaro, A., 658
 Cattelan, A. M., 619
 Caumes, E., 227, 811
 Cave, M. D., 356
 Cegielski, P., 288
 Celum, C. L., 261
 Cerón, A., 981
 Cetron, M. S., 71, 520
 Chaiprasert, A., 29
 Chakraborty, H., 742
 Chambers, M. A., S283, S299
 Chambers, S. T., 382
 Chan, R. M. T., 882
 Chan, W.-m., 882
 Chanbancherd, P., 819
 Chandrasekar, P. H., 403, 984
 Chang, F. Y., 322
 Chapman, S. W., 679, 684
 Chechko, S., 954
 Chen, T.-W., 823
 Cheng, V. C. C., 882
 Cherry, J. D., 534
 Chesney, M. A., S171
 Chetchotisakd, P., 29, 877
 Chevalier, B., 840
 Chez, M. G., 213
 Chiaramondia, M., 947
 Chien, J. W., 146
 Chintu, C., S309
 Chiu, C.-H., 239
 Chocarro Martinez, A., 234
 Choonhakarn, C., 29
 Chou, Y.-H., 823
 Chowfin, A., 969
 Christensson, B., 585
 Christopher, G. W., 843
 Chuck, S. K., 433
 Cieslak, P. R., 515
 Cieslak, T. J., 843
 Cinque, P., 95
 Cinti, S. K., 511
 Cioecchini, M., 222
 Ciuffreda, D., 962
 Clark, C., 764
 Clark, N. M., 403
 Clark, R., 407
 Cleavinger, P. J., 176
 Clemons, K. V., 328
 Cloud, G., 47
 Cobo, J., 55
 Cobo-Soriano, R., 306
 Cockle, P. J., S291
 Coffin, S. E., 179
 Cohen, A. H., 500
 Cohen, J., 961
 Cohen, M. S., 736, 742
 Cohen, S. H., 952
 Cohn, S. E., 749
 Colin, D., 227
 Collado, A., 461
 Commander, N., S283
 Comstock, G. W., S250
 Conetta, R., 413
 Connolly, P., 877
 Conway, B., S130
 Cook, J. L., 444
 Cook, R. L., 406
 Coppola, S. J., 78
 Cordeiro, S. M., 78
 Cordero, E., 461

- Corey, G. R., 633
 Corey, L., 261
 Cortés, C., 306
 Costa, D., 831
 Costello, C. N., 534
 Côté, H. C. F., S117
 Cotter, P. A., 534
 Crane, L. R., 511
 Cruceta, A., 392
 Culpepper, R. C., 843
 Cunha, B. A., 237
 Cunningham, A. L., 549
 Cunningham, E. T., 232
 Curley, G. V., 595
 Currier, J. S., S66
 Cynamon, M. H., S288
 Dagan, R., 319, 419
 D'Agostino, A. N., 349
 Dalovisio, J. R., 639
 d'Amati, G., 825
 Dance, D. A. B., 235
 Dankner, W. M., 356
 Darmstadt, G. L., 408
 Davidson, P., 293
 Davidson, R. N., 764
 Davies, A., S299
 Davis, C. E., 356
 Davis, T. E., 29
 Daza, R. M., 603
 Deckelbaum, R. J., 419
 Deeks, S. G., S177, 504
 Deep, A. E., 65
 De Groot, M. A., 87, 226, 582
 Del Bono, V., 947
 del Giudice, P., 201, 820
 Dellamonica, P., 201
 De Mauleon, P., 840
 Denison, E. K., 618
 Denning, D. W., 41, 696
 Dennis, D. T., 893
 De Pauw, B., 41
 Derchi, L. E., 947
 Derossi, A., 300
 DeSimone, J. A., 384
 DeStefano, M. S., S288
 Dhillon, S. S., 572
 Dickstein, B., 569
 Didier, C., 840
 Dillaha, J. A., 399
 Di Pietro, M., 962
 DiSalvo, A. F., 328
 Dismukes, W. E., 14, 19, 47, 653, 662, 710
 Doern, G. V., 166
 Domingo, P., 615
 Donepudi, R., 629
 Dotevall, L., 410
 Dowell, S. F., 784
 Downey, M. S., 590
 Dummer, S., 696
 Durant, J., 201
 Dworkin, M. S., S5, 241, 955
 Ebinger, M., 606
 Edlin, B. R., 579
 Edwards, J. E., 662
 Eichenauer, E., 938
 Eitzen, E. M., Jr., 843
 Ekwall, E., 770
 Eliadis, K., 567
 Ellner, J. J., S279
 El-On, J., 419
 Emmanouilides, C., 790
 Engel, G., 215
 Engelmann, H., 342
 Epstein, J. S., 35
 Ernst, C., 986
 Eron, J. J., Jr., S160
 Eschelman, D. J., 384
 Eschenbach, D. A., 901
 Ettestad, P., 893
 European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Intergrupe Français du Myélome, 41
 Evans, J., 820
 Evans, T. G., 608
 Evengård, B., 770
 Eykyn, S. J., 336
 Falagas, M. E., 567
 Falloon, J., 313
 Farley, M. M., 71, 520
 Farver, C. E., 595
 Fearon, W. F., 215
 Fedele, F., 825
 Feinberg, J., 749
 Feldman, P. A., 982
 Feray, C., 820
 Fernandez, M., 282
 Ferraro, M. J., 799
 Ferrieri, P., 276
 Feuilhade, M., 820
 Fichtenbaum, C. J., 749
 Figueras, M. J., 988
 Filler, S. G., 662
 Fine, M. J., 520
 Fiore, A. E., 71
 Fiorelli, M., 825
 Fiorentino, G., 831
 Fischer, T., 219
 Fish, D. N., 908
 Fitzgerald, E. A., 35
 Flack, N. P., 587
 Flanagan, A. M., 764
 Fleming, D. W., 515
 Fletcher, C. V., S151
 Flores, A. E., 276
 Fluit, A. C., 454
 Fong, I. W., 757
 Fong, M. W., 757
 Ford, B., 971
 Fouché, R., 201
 Fowler, V. G., Jr., 633
 Frame, P., 749
 Franco, S. M., 191
 Frank, A. L., 630
 Fraser, D., 419
 Frederick, T., S5
 Freedberg, K. A., S15, S85
 Frias, C., 576
 Friedman, M. S., 984
 Friesen, P. P., 946
 Fritz, C. L., 893
 Frontera, J. A., 374
 Fujisawa, H., 380
 Fukuda, S., 529
 Furrer, H., 943
 Furuta, Y., 529
 Gage, K. L., 893
 Galgiani, J. N., 658
 Gallart, M. T., 392
 Gallego, J. C., 603
 Gallis, H. A., 14
 Gallo, P., 825
 Gallucci, M., 223
 Galvão Reis, M., 78
 Garbutt, J. M., 466
 Garcia, F., 392
 Garcia Garcia, I., 234
 Garner, R., 736
 Gatell, J. M., 392
 Gathe, J. C., Jr., 491
 Gaydos, C. A., 719
 Gaydos, J. C., 719
 Gayowski, T., 322
 Gelberg, L., 293
 Gennaro, M. L., S243
 Gennesin, Y., 152
 Gerber, J. G., S123
 Gildenberg, P. L., 491
 Ginsberg, A. M., S199, S233
 Ginsberg, M. M., 618
 Giobbia, M., 223
 Girón, J. A., 461
 Gisbert, J. P., 976
 Giudici, B., 95
 Glassroth, J., S229
 Gnann, J. W., Jr., S72
 Goldman, M., 141
 Goldsmith, L. J., 191
 Goldwater, P. N., 984
 Gómez-Mateos, J., 461
 González-Diego, P., 55
 González-García, J. J., 915
 Gonzalez Lopez, A., 234
 González-Serrano, M., 461
 Goodman, E. L., 234
 Goodnough, S., 425
 Goossens, H., 473
 Gorbach, S. L., 1
 Gori, A., 962
 Gornbein, J. A., 534
 Gottlieb, T., 942
 Gouveia, E. L., 78
 Gradon, J. D., 374
 Gradstein, S., 319
 Graham, J. V., 609
 Graham, R., 425
 Grant, R. M., 504
 Graybill, J. R., 47
 Graybill, R. J., 710
 Gredlein, C. M., 590
 Greer, R. W., 605
 Griffin, J. F. T., S223
 Griffith, D. E., 288
 Grimaldi, A., 831
 Grimon, F., 395
 Gross, P. A., S85
 Guarro, J., 988
 Guest, J. L., 410
 Guex, A.-C., 602
 Guglielminotti, J., 209
 Guglielmo, B. J., 205
 Guidet, B., 209
 Gupta, R., 454
 Gurgui, M., 615
 Gwaltney, J. M., Jr., 387
 Habbema, J. D. F., S309
 Hacini, J., 395
 Hagberg, L., 410
 Hagman, H. M., 349
 Hajjeh, R., 61, 684, 877
 Halachmi, S., 982
 Hall, B., 599
 Halvorsen, S., 643
 Hamill, R., 47, 688
 Hammarström, V., 342
 Hamrick, H. J., 627
 Han, S.-R., 219
 Handa, A., 569
 Handsfield, H. H., 839
 Hansen, N. C., 35
 Hanson, D. L., S5, 955
 Harbarth, S., 990
 Harel, L., 500
 Harrell, L., 870
 Harrigan, P. R., S117
 Harris, C., 198
 Harrison, L. H., 71, 648
 Haslett, P. A. J., 224, 540
 Hausdorff, W. P., 100, 122
 Hayden, F. G., 587
 Hayden, M. K., 630
 Hedlund, K. O., 770
 Heifets, L. B., 444
 Helmreich-Becker, I., 219
 Henderson, D. A., 926
 Hendley, J. O., 387
 Henning, K. J., 384
 Henry, D., 587
 Heraud, J. M., 188
 Herbrecht, R., 41
 Hernández-Albujar, S., 915
 Hernández-Quero, J., 461
 Heussel, C. P., 219
 Hewinson, R. G., S283, S291, S299
 Hickman, M. E., 282
 Hillier, S., 276
 Hindler, J., 790
 Hirsch, C. S., S279

- Ho, J., 757
 Ho, P. L., 989
 Hocqueloux, L., 940
 Hoffman, I. F., 736, 742
 Hofmann, J., 520
 Hoft, D. F., S217, S257
 Holgado, W., 65
 Holland, F., 749
 Hollender, E. S., 779
 Holmberg, S., S5
 Holmes, K. K., S1, S15
 Holtgrave, D., S15
 Holtzer, C., 232
 Hommel, D., 188
 Hook, E. W., III, 540
 Hooke, J., 936
 Hooke, M., 936
 Hooper, D. C., 243
 Hooton, T. M., 901
 Horsburgh, C. R., Jr., S213
 Hsue, G., 534
 Huang, J. S., 504
 Huang, S. S., 504
 Huber, C., 219
 Huitt, G. A., 444
 Hukkanen, V., 363
 Hulin, A., 188
 Hurwitz, S., 540
 Imakita, M., 611
 Inglesby, T. V., 926
 Ishibashi-Ueda, H., 611
 Ito, Y., 185
 Jackson, L. A., 534
 Jacobs, R. A., 205
 Jacobson, K. L., 965
 Jacobson, M. A., 232
 Jaffe, H. W., S72
 Janco, J., 319
 Jarvis, W. R., 35, 270
 Jenkins, P. R., 723, 730, 736, 742
 Jenkins, R. A., 723, 730, 736
 Jenny-Avital, E. R., 409
 Jeronimo, S. M. B., 608
 Jiménez de Anta, M. T., 368
 Jirarattanapochai, K., 29
 Johnson, J. R., 234, 836, 838
 Johnson, P., 688
 Johnson, R. H., 658
 Johnson, W. D., Jr., 78
 Jones, D., 779
 Jones, J. L., S5
 Jones, K. C., 270
 Jones, M. E., 454
 Jonsson, G., 342
 Jorgensen, J. H., 71, 799
 Jubran, R. F., 569
 Judson, M. A., 696
 Juneau, J., 639
 Kahler, L., 425
 Kain, K. C., 401
 Kaiser, L., 587
 Kakuda, T. N., S151
 Kan, V. L., 621, 696
 Kao, A., 61
 Kaplan, J. E., S1, S5, S15
 Karagas, M. R., S309
 Karchmer, A. W., 14, 19, 609
 Kärnell, A., 770
 Kateiva, J., 639
 Kauffman, C. A., 14, 19, 403, 679, 684, 688
 Kaufman, L., 61
 Kaul, D. R., 511
 Kavlick, M. F., 313
 Kawabata, H., 529
 Kazanjian, P. H., 511
 Keene, O., 587
 Keiser, P., 949
 Kelkar, S., 630
 Keller, M., 599
 Kelly, J. J., 985
 Kern, V. L., 195
 Keysary, A., 214
 Keystone, J. S., 401
 Khatib, R., 396
 Khawplod, P., 218
 Kierulf, P., 643
 Kim, J. H., 491
 Kimura, H., 185
 Kitahata, M. M., S85
 Kite-Powell, K., 221
 Klein, D. L., S302
 Kloek, C., 122
 Klugman, K. P., 473
 Knowles, L., 293
 Ko, A. I., 78
 Ko, W.-C., 473
 Kobayashi, J., 61
 Koehler, H. H., 219
 Kohler, R., 629
 Kolczak, M. S., 71
 Koletar, S., 749
 Kontaxis, A., 567
 Kontoyiannis, D. P., 851
 Kortepeter, M. G., 843
 Kosek, J. C., 215
 Kral, A. H., 579
 Kraus, D. H., 625
 Kreiss, J., 486
 Kroeber, A., 790
 Krohn, M. A., 276
 Kroll, J. S., 624
 Krone, M. R., 261
 Kropf, P., 764
 Kucia, M. L., 146
 Kumari, P., 621
 Kuritzkes, D. R., 256
 Kursh, E. D., 595
 Labarca, J. A., 195
 Lacey, C. J., 549
 Lacroix, C., 820
 LaFon, S., 313
 Lagergren, A., 770
 Lam, L. L., 221
 Lamas, C. C., 336
 Lane, H. C., 313
 Larsen, R. A., 710
 Larwood, T. R., 612
 Lasheras, D., 55
 Lassak, M., 406
 Laut, J., 198
 Lauzurica, R., 576
 Lavreys, L., 486
 Lazzarin, A., 95, 962
 Leber, A. L., 195
 Leder, K. S., 622
 LeDoux, M. S., 211
 Lee, C.-C., 823
 Lee, C.-H., 141
 Lee, J. Y., 14, 19
 Lee, M. B., 401
 Lee, M.-L. T., 276
 Leib, S. L., 837
 Lein, A. D., S309
 Lellouche, N., 209
 Li, H., 176
 Li, J. S., 633
 Libshitz, H. I., 965
 Lietman, T., S316
 Lin, T.-Y., 239
 Linde, A., 342
 Lindegren, M. L., S5
 Lindholm-Levy, P., 444
 Lippek, F., 938
 Lipton, A., 534
 Lisiewicz, J., S193
 Littenberg, B., 466
 Ljungman, P., 342
 Lo, B., 757
 Lôbo, T. S., 78
 Löfdahl, S., 770
 Lopez-Garrido, M. J., 400
 Lori, F., S193
 Lortholary, O., 41
 Lotric-Furlan, S., 987
 Loutit, J. S., 215
 Lowrie, D., S283
 Lowther, S. A., 955
 Loyd, J., 688
 Luban, N. L. C., 569
 Luber, A. D., 205
 Lucena, M. I., 400
 Lüke, W., 95
 Ma, E. S. K., 882
 Mackin, G. A., 226
 Madeb, R., 982
 Madi, N. M., S201
 Madnick, E. G., 349
 Madon, E., 222
 Maeurer, M. J., 219
 Malkin, M., 625
 Mallolas, J., 182
 Manavathu, E., 984
 Mandaliya, K., 486
 Mandell, W., 613
 Manfrin, V., 210
 Mangi, R., 14
 Mangum, M. E., 627
 Manion, D. J., 313
 Mann, S., 942
 Manneke, B., 606
 Mantella, A., 210
 Marcinek, J. F., 630
 Marco, F., 368
 Margolis, T. P., 232
 Marino, I. R., 322
 Marinus, A., 41
 Marmont, A., 222
 Marra, C. M., 540
 Marsh, P. D., S299
 Marshall, B. G., 764
 Marston, B., 410
 Martin, H. L., Jr., 486
 Martin, J. W., 936
 Martínez, J. A., 368
 Martínez-Murcia, A., 988
 Martinic, C., 840
 Martino, S., 222
 Martinoli, C., 947
 Mast, E. E., S77
 Masur, H., S1, S15, 313
 Maury, E., 209
 Mawhorter, S. D., 595
 Max, B., S96
 May, H., 198
 Maytan, M., 922
 Mazzarello, G., 947
 McArthur, J. C., 540
 McCombs, S. B., 241
 McCormack, J. G., 473
 McCullough, M. J., 328
 McCune, J. M., 504
 McDermott, L., 870
 McKee, K. T., Jr., 723, 730, 736, 742
 McKellar, P. P., 816
 McKinsey, D. S., 14, 19, 87, 688
 McMurray, D. N., S210
 McNeil, S. A., 403
 McPhaul, L., 599
 Meier, A., 901
 Melnick, D. A., S85
 Meneghetti, F., 619
 Meng, Y.-X., 221
 Mensa, J., 368
 Merino, M. D., 461
 Metlay, J. P., 520
 Mick, N., 633
 Miedouge, M., 395
 Miller, L. G., 293
 Miller, S., 545
 Miller, W. C., 742
 Mindel, A., 549
 Minozzi, C., 820
 Mirels, L. F., 349
 Miro, J. M., 392
 Mirón, M., 397
 Mitchell, P. S., 176
 Mitchell, S., 969
 Mitsuya, H., 313

- Mizock, B. A., 229
 Mohan, U. R., 624
 Mohapatra, S., 473
 Mokrzycki, M. H., 198
 Monno, L., 831
 Monsuez, J.-J., 820
 Montaner, J. S. G., S143
 Montoya, J., 981
 Mootsikapun, P., 29
 Morandini, B., 962
 Moreau, P., 41
 Moreira, A. L., 224
 Moreno-Martínez, A., 368
 Morin, P., S309
 Morishima, T., 185
 Moroney, J. F., 71
 Morris, A. J., 870
 Morrison, V. A., 696
 Morse, A., 407
 Moscona, A., 857
 Mosher, A., 14
 Moylett, E. H., 282
 Mukherji, S. K., 627
 Mulazimoglu, L., 473
 Mulholland, K., S206
 Müller, I., 764
 Mundy, L. M., 466
 Muñoz, I., 368
 Muñoz, P., 306
 Muñoz, R. M., 603
 Murakami, T., 185
 Murali, R., 613
 Murdoch, D. R., 382
 Murphy, D. T., 288
 Murphy, R. L., S95
 Murray, K., 764
 Musher, D. M., 25
 Mustafa, A. S., S201
 Mwinga, A., S309
 Mygind, N., 387
 Mylotte, J. M., 425
 Nadelman, R. B., 545, 818
 Naggan, L., 419
 Nannis, E. D., 723, 730, 736
 Narita, M., 779, 405
 Naso, A., 619
 National Institute of Allergy
 and Infectious Diseases My-
 coses Study Group, 14, 19,
 47
 Nativ, O., 982
 Nauschuetz, W. F., 534
 Ndinya-Achola, J. O., 486
 Nettles, R., 633
 Nevin, T., 540
 Ng, V. L., 504
 Ng, Y.-Y., 823
 Nguyen, M. H., 870
 Nichterlein, T., 606
 Nieman, R. E., 985
 Nolasco, D., 65
 Nomura, T., 380
 Nowakowski, J., 545
 Nucci, M., 300
 Nuño, E., 461
 Öberga, G., 342
 O'Brien, K. L., 784
 O'Brien, W. A., S185
 Offenstadt, G., 209
 Oftung, F., S201
 Ogbolu, C., 954
 Ogbukiri, T., 407
 Ohtani, F., 529
 Oliver, A., 55
 Ono, C. M., 534
 Onorato, I. M., 617
 Orloski, K. A., 893
 Ormerod, L. D., 479
 O'Toole, T., 926
 Otsuka, F., 380
 Ou, J. T., 239
 Øvstebo, R., 643
 Owens, D. K., 157
 Pachón, J., 461
 Pages, C. L., 940
 Pajares, J. M., 976
 Palacios, M., 55
 Paletta, D., Jr., 205
 Palmisano, J., 198
 Pancharoen, C., 218
 Pandian, N. G., 825
 Pankey, G. A., 696
 Panosian, C., 816
 Panzer, H., 19
 Papagno, L., 962
 Pape, W. J., 893
 Pappagianis, D., 61
 Pappas, P. G., 65, 662, 679, 710
 Paradise, M., 261
 Paradiso, P. R., 100, 122
 Park, P., 328
 Passeron, J., 820
 Pastore, G., 831
 Paterson, D. L., 322, 473
 Patterson, J. E., 71
 Patterson, T. F., 696
 Patton, D. L., 901
 Pau, C.-P., 221
 Pauksen, K., 342
 Pavlin, J. A., 843
 Pearson, R. D., 608
 Peeling, R., 946
 Pegues, D. A., 195
 Pellett, P. E., S72, 221
 Peña, J. M., 915
 Pérez-Díaz, J. C., 55
 Perfect, J. R., 710
 Pericas, R., 615
 Perkins, B. A., 212
 Perla, E. N., 935
 Perrin, C., 201
 Persing, D. H., 176
 Petit, D., 840
 Phan, H. M., 25
 Phanuphak, P., 218
 Phillips, C. D., 387
 Phillips, P., 971
 Pick, N., 214
 Pinel, C., 820
 Pinheiro, R. M., 78
 Piscitelli, S. C., S15, 313
 Pitchenik, A. E., 779
 Pitlik, S., 240
 Plana, M., 392
 Platt, R., 276
 Plotkin, S. A., 4
 Pontali, E., 947
 Popovic, T., 212
 Porat, N., 319
 Potasman, I., 214
 Pottage, J., 749
 Pourriere, M., 840
 Powderly, W. G., 47, 710, 749
 Poza, G., 981
 Pretolesi, F., 947
 Puklin, J. E., 479
 Pulcheri, W., 300
 Pumarola, T., 392
 Quinlisk, P., 784
 Quinn, J. P., 630
 Quinn, T. C., 719
 Raad, I., 965
 Rabalais, G. P., 191
 Raber, S. R., 433
 Rabkin, C. S., 762
 Radziwill, A. J., 602
 Rahmani, D., 952
 Ramanathan, J., 396
 Raz, R., 152
 Redondo, C., 981
 Reed, S. L., 959
 Regnery, H., 784
 Reichler, M. R., 617
 Reis, J. N., 78
 Reller, L. B., 165
 Rench, M. A., 276, 282
 Replogle, M. L., 515
 Reppen, M. L., 270
 Rex, J. H., 662
 Reyes, M. P., 479
 Reynolds, P. J., 893
 Rhodes, L. V., III, 582
 Rhodes, S., S291
 Ribeiro Dourado, C. M., 78
 Ribera, J. M., 576
 Ricaurte, J. C., 613
 Richart, C., 397
 Rigoli, R., 223
 Riley, L. W., 78
 Rimland, D., 410
 Rinaldi, M. G., 349
 Rinaldo, C. R., 406
 Riser, L., 47
 Rivero, A., 461
 Rocha, H., 78
 Rodrigo, L., 400
 Rodríguez-Créixems, M., 306
 Rodríguez-Tudela, J. L., 981
 Rodvold, K. A., 433
 Rogers, M., 313
 Rollo, M. A., 831
 Rolston, K. V. I., 851, 965
 Romero, M. L., 174
 Ros, P., 55
 Rosenfeld, S., 152
 Rosen Krands, I., S201
 Rosenstein, N. E., 212
 Rotschafer, J. C., 440
 Rottensterich, E., 152
 Rouleau, D., S143
 Rowe, J. R., 843
 Royo, A., 915
 Rudich, H., 500
 Ruhinke, M., 938
 Ruiz, J., 981
 Ruth, A., 179
 Ruxrungtham, K., 218
 Ryan, T., 633
 Rybold, D. J., 579
 Rzotkiewicz, S., 214
 Saag, M. S., 47, 710, 749
 Sadler, B., 313
 Safdar, A., 625
 Sagui, E., 840
 Sahouri, M. J., 479
 Sakaguchi, L. K., 534
 Salata, R. A., 146
 Salgado, K., 78
 Salmerón, J., 400
 Salmon, J. E., 25
 Sampson, B. A., 413
 Sánchez, F., 368
 Sanders, J. W., 936
 Sandler, R. H., 213
 Sapkas, G., 567
 Saracco, A., 962
 Sarosi, G., 688
 Sax, P. E., 511
 Scarparo, C., 210
 Scheckler, W. E., 270
 Schiller, G. J., 236
 Schmidt, D., 606
 Schmitz, F.-J., 454
 Schmitz, J. L., 736
 Schreckenberger, P. C., 630
 Schrift, M. J., 213
 Schuchat, A., 71
 Schumacher, U. K., 606
 Schwartz, B., 784
 Schwelke, J. R., 986
 Scott, L. L., 549
 Scotton, P. G., 223
 Searle, J., 938
 Seeff, L. B., S77
 Segovia, J., 603
 Sellier, P., 820
 Sellman, J., 784
 Sen, P., 954
 Seña, A. C., 742
 Sexton, D. J., 633
 Shaban, F., S201
 Shah, S. S., 179

- Sharkey, P. K., 14
 Shatsky, S., 349
 Shaw, R. J., 764
 Shen, C., 946
 Sherer, R., S96
 Sherman, D. S., 908
 Shimoni, Z., 240
 Shinnick, T. M., S276
 Shiomi, M., 185
 Shiraki, K., 611
 Shoen, C. M., S288
 Shutt, K., 877
 Siakavellas, E. C., 567
 Siber, G. R., 100, 122
 Siddiqui, A. H., 174
 Siegman-Igra, Y., 986
 Silva, J., Jr., 952
 Silveira, F., 300
 Silverman, M. L., 590
 Simarro, E., 981
 Simpson, G., 540
 Singh, N., 322
 Sirvent, J. J., 397
 Sisson, B. A., 191
 Siton, Y., 319
 Sivak, S., 545
 Sjölin, J., 342
 Skiest, D. J., 949
 Smith, A. L., 35
 Smith, D. S., 444
 Smith, E. M., 270
 Smith, H., 582
 Smith, J. W., 141
 Smith, T. F., 176
 Snider, D. E., Jr., S271
 Snyderman, D. R., 870
 Sobel, J. D., 14, 19, 47, 652, 662, 710
 Solano, T., 942
 Solza, C., 300
 Soriano, A., 368
 Soriano, E., 368
 Sousa, A. Q., 608
 Spanish Cidofovir Study Group, 182
 Spector, N., 300
 Spell, D. W., 605
 Spira, T. J., 221
 Spruance, S. L., 549
 Squier, C., 322
 Srisakandian, S., 961
 Srugo, I., 982
 Stambaugh, J. J., 779
 Stamey, F. R., 221
 Stamm, W. E., 152, 901
 Stanberry, L. R., 268, 549
 Stanley, H., 232
 Stapleton, A. E., 901
 Stefanova, R., 356
 Stein, J. D., 893
 Steiner, F., 629
 Stevens, D. A., 328, 349, 658, 696
 St. George, K., 406
 Stocker, S. A., 212
 Stoeckli, T. C., 226
 Stoler, Z., 152
 Stone, F., 954
 Straussberg, R., 500
 Strle, F., 987
 Suárez-Leoz, M., 306
 Sugar, A. M., 14
 Sulkowski, M. S., S77
 Svensson, L., 770
 Svenungsson, B., 770
 Swaminathan, A., 954
 Swiss HIV Cohort Study, 943
 Symmans, W. F., 224
 Szurgot, J. G., 605
 Tabet, S. R., 261
 Tachdjian, R., 534
 Talarmin, A., 188
 Tambosis, E., 942
 Tambussi, G., 962
 Tancik, C. A., 399
 Tang, W. M., 989
 Tang, X., 141
 Tang, Y. J., 952
 Tang, Y.-W., 176
 Tantawichien, T., 218
 Tarrand, J., 965
 Tascon, R., S283
 Tasker, S., 87
 Tateishi, T., 380
 Tavares-Neto, J., 78
 Teira, R., 965
 Teixeira, A. A., 413
 Teixeira, M. J., 608
 Tellez, I., 65
 Temoshok, L. R., 723, 730
 Tenover, F. C., 212
 Territo, M. C., 195, 790
 Thielking, P., 608
 Thisyakorn, U., 218
 Thomas, C., 19
 Thomas, D. L., S77
 Thompson, M. L., 486
 Thwin, S. S., 901
 Thys, J.-P., 838
 Tice, A., 839
 Tight, R., 969
 Tiu, C.-M., 823
 Tokars, J. I., 35, 270
 Tonon, E., 223
 Torres, J., 141
 Torres-Tortosa, M., 461
 Tortoli, E., 10, 831
 Tosteson, A. N. A., S309
 Tovo, P.-A., 222
 Toy, C., 757
 Trenholme, G. M., 473
 Trevenzoli, M., 619
 Trick, W. E., 270
 Tsang, T. H. F., 618
 Tsiodras, S., 609
 Tucker, R. M., 349
 Tvaroha, S., S309
 Ubol, P. N., 29
 Ubolyam, S., 218
 Ullmann, A. J., 219
 US Public Health Service/Infectious Diseases Society of America Prevention of Opportunistic Infections Working Group, S29
 Vachon, F., 940
 Vaglia, A., 223
 Vail, G., 629
 Valway, S. E., 617
 van der Horst, C., 47, 540, 749
 Van Dyke, R., S15
 Vaquero, M., 576
 Vayre, F., 820
 Vaz, B., 95
 Vazquez, G., 615
 Vazquez, J. A., 14, 19
 Vázquez, J. J., 915
 Venczel, L. V., 618
 Ventrapragada, M., 466
 Verhoef, J., 454
 Vidal, C., 392
 Vidal, F., 397
 Vila, N., 981
 Villanueva, A. V., 479
 Vincent, J. M., 534
 Vittecoq, D., 820
 Vogel, F. R., S266
 Vogel, S., 313
 Vold Pepper, P., 157
 Von Gottberg, A., 473
 von Reyn, C. F., S309
 Vordermeier, H. M., S283, S291
 Vugia, D. J., 618
 Waddell, R. D., S309
 Waecker, N. J., Jr., 356
 Wagener, M. M., 322
 Wagener, M. W., 870
 Walawander, A., 749
 Wald, A., 261
 Waldman, G., 413
 Wallace, R. J., Jr., 288
 Walsh, T. J., 662, 696
 Walters, M. I., 784
 Walters, S., 624
 Wan, P.-C. T., 241
 Wang, S. A., 35
 Wang, Z., 823
 Wasser, J., 152
 Watanakunakorn, C., 238, 572
 Watine, J., 395
 Watt, G., 819
 Watts, H., S15
 Weber, G., 319
 Weber, T., 95
 Weinberg, E. D., 991
 Weinberger, M., 240
 Weinstein, M. P., 165
 Weintraub, A., 770
 Welch, K., 407
 Wessel, V. C., 851
 Whalen, C. C., S279
 Wheat, J., 688
 Wheat, L. J., 3, 29, 141, 877
 Whelan, A. O., S283, S291
 Whimbey, E., 965
 White, D. R., 627
 White, N. J., 836
 Whitney, C., 520
 Widell, A., 585
 Wiebe, T., 585
 Wilde, H., 218
 Williams, A., S299
 Williams, B., 877
 Williams, H. V., 618
 Williams, P. L., 349, 658
 Wilson, M. E., S262
 Winstead, J. M., 87
 Winston, D. J., 236, 790
 Winter, C., 901
 Winther, B., 387
 Wise, G. J., 14
 Wong, S. S. Y., 882
 Worku, S., S257
 Wormser, G. P., 545
 Wurtz, R., 817
 Yabuta, Y., 185
 Yagupsky, P., 319
 Yang, H.-M., 823
 Yang, W.-C., 823
 Yao, J., 825
 Yebra, M., 603
 Yee, A. M. F., 25
 Yeh, S. H., 599
 Yiannoutsos, C., 749
 Yoshikawa, T. T., 931
 Yoshimura, K., 313
 Young, D. B., S254
 Young, L., 425
 Young, L. S., 235
 Young, N. S., 569
 Yu, E. I., 293
 Yu, V. L., 473, 870
 Yuen, K.-y., 882, 989
 Yutani, C., 611
 Zala, C., S143
 Zaleznik, D. F., 276
 Zangwill, K. M., 599
 Zervos, M., 19
 Zier, K., 934
 Zimmerli, W., 837
 Zumla, A., S309
 Zuniga, R., 25

Subject Index

- Abacavir, for HIV infection, 313
 adverse effects, S96
 resistance to, S185
- Abdominal infections
 due to *Aspergillus*, practice guidelines, 696
 due to *Staphylococcus aureus*, methicillin-resistant, in liver transplantation, 322
 treatment with quinolones, 243
- Abscess
 brain
 due to *Aspergillus*, practice guidelines, 696
 due to *Salmonella typhimurium*, 621
 due to *Streptococcus intermedius*, 396
 due to *Capnocytophaga granulosa*, 606
 epidemiology, in injection drug users, 579
 liver, due to *Staphylococcus aureus*, in chronic granulomatous disease, treatment with granulocyte-macrophage colony-stimulating factor, 222
 parapharyngeal, in cat-scratch disease, 599
 paraspinal, due to *Peptostreptococcus micros*, 622
- ABT-378, for HIV infection, S160
- Acidosis, lactic, due to stavudine, 198
- Acinetobacter* infections
 bacteremia, antibiotic susceptibility surveillance, 454
 resistance in, 454
- Acquired immunodeficiency syndrome (see Human immunodeficiency virus infection)
- Acyclovir
 for herpes simplex virus encephalitis, 185
 prophylactic
 for lymphoma, in HIV infection, 757, 762
 for opportunistic infections, S25, S29
- Adefovir, for HIV infection
 adverse effects, S96
 resistance to, S185
- Adjuvants, for vaccines, S266
- Aeromonas* infections
 clinically relevant species, 988
 diarrhea
 in Swedish adults, 770
- AG-1776, for HIV infection, S160
- Aging, epidemiology, infectious disease and, 931
- AIDS (see Human immunodeficiency virus infection)
- Alatrofloxacin, state-of-the-art, 243
- Albendazole, for cutaneous larva migrans, 811
- Albumin, *Enterobacter cloacae* contamination of, 35
- Allergic bronchopulmonary aspergillosis, practice guidelines, 696
- Alternariosis, skin, 13, 174
- Amikacin, extended-interval dosing, national survey, 433, 440
- Aminoglycosides
 extended-interval dosing, national survey, 433, 440
 for *Mycobacterium terrae* infections, 444
 resistance to, enterococci, 799
- Amniotic fluid, herpes simplex virus type 2 in, 363
- Amoxicillin, for *Streptococcus pneumoniae* pneumonia [letter and reply], 234
- Amphotericin B
 for aspergillosis, 696
 for blastomycosis, 679, 969
 for candidiasis, practice guidelines, 662
 for coccidioidomycosis, 658
 for cryptococcosis, 710
 in HIV infection, 47
 practice guidelines for, 653, 662
 for histoplasmosis, 595, 688
 lipid formulations
 practice guidelines for, 653
 for invasive infections [letter], 236
 prophylactic
 for neutropenia, 300
 for opportunistic infections, S25
 for sporotrichosis, 684
 for urinary tract infections, 14
 for zygomycosis, 851
 Ampicillin, resistance to, *Shigella*, 515
 Amprenavir, for HIV infection, S160, 313
 adverse effects, S96
 in drug combinations, S160
 pharmacodynamics, S151
 Anaerobic bacteria, susceptibility testing, 799
Ancylostoma braziliense infections, larva migrans in, treatment, 811
 Aneurysm, aortic
 due to *Chlamydia pneumoniae*, 946
 due to *Staphylococcus aureus*, in dialysis, 823
- Animal models
 tuberculosis treatment, S288
 tuberculosis vaccination
 domestic livestock, S222
 guinea pigs, S299
 livestock, S283, S291
 mouse, S283
 primate, S210
 wildlife, S222
- Animals, opportunistic infections from, prophylaxis, S29
- Anthrax, vaccination, 843
- Antibiotics (see also specific antibiotics)
 intravenous, home program for, managed care financial impact, 639
 new treatment options, June News and Events
 prophylactic (see Prophylaxis)
 resistance to (see Drug resistance)
 shortage, February News and Events
 susceptibility testing (see Susceptibility testing)
- Antifungal drugs (see also specific drugs and infections)
 practice guidelines for, 653
- Antiretroviral agents, for HIV infection (see also highly active antiretroviral therapy; (specific drugs)
 adherence issues in, S96, S171
 adverse effects, S96
 combinations in, S123
 drug interaction optimization, S123
 hydroxyurea adjuvant with, S143, S193
 lipodystrophy syndrome due to, S135
 pharmacodynamics, S151
 pharmacokinetics, S123
 protease inhibitors, S160
 protease inhibitor-sparing regimens, S130
 resistance to, S117, S185
 virologic response to, S177
- Aorta, mycotic aneurysm
 due to *Chlamydia pneumoniae*, 946

- due to *Staphylococcus aureus* in dialysis, 823
- Aortic valve, bicuspid, endocarditis in, 336
- Arthralgia
 - in HIV infection, primary, in African women, 486
 - in parvovirus B19 infections, 500
- Arthritis
 - due to *Histoplasma capsulatum*, practice guidelines, 688
 - due to Lyme disease vaccine, May News and Events
 - septic
 - due to *Candida*, practice guidelines, 662
 - due to *Clostridium*, 590
- Aspergilloma, practice guidelines, 696
- Aspergillosis
 - fulminant, in malaria, 938, 940
 - immunorestitution disease in, 882
 - invasive, practice guidelines, 696
 - in multiple myeloma, 41
 - nosocomial [letter], 984
 - practice guidelines, 696
 - prophylaxis, in neutropenia, 300
 - sinusitis, pneumocephalus in, 215
- Asthenia, due to antiretroviral agents, S96
- Astrovirus infections, diarrhea, in Swedish adults, 770
- Ataxia, in tularemia, 211
- Atovaquone, prophylactic, for opportunistic infections, S25, S29
- Azithromycin
 - for *Mycobacterium avium* complex infections, 288
 - prophylactic, for opportunistic infections, S25, S29
- Bacille Calmette-Guérin
 - chemotherapy solution contamination with, 356
 - vaccination with
 - disadvantages, S233
 - efficacious strain identification in, S250
 - efficacy, S262
 - animal models, S299
 - ethical issues in, S271
 - geographical effects on, S262
 - historical background, S262
 - mucosal, S217
 - vs. *Mycobacterium bovis* infections, S291
 - primate model, S210
 - T lymphocyte response in, S257
 - in transplantation, 857
 - trial design, S206
 - trials, S213
 - veterinary, S222
- Back pain, in echinococcal cyst, 442, 567
- Bacteremia
 - antibiotic susceptibility surveillance, 454
 - due to *Bacteroides*, prospective observational trial, 870
 - due to *Chlamydia pneumoniae*, aortic aneurysm in, 946
 - due to *Enterobacter cloacae*, nosocomial, 35
 - due to *Enterococcus faecium*
 - treatment with linezolid, 403
 - vancomycin-resistant
 - mortality in, 466
 - treatment with quinupristin/dalfopristin, 790
 - epidemiology, in rehabilitation unit, 425
 - due to *Klebsiella pneumoniae*, ciprofloxacin-resistant, 473
 - due to *Moraxella osloensis*, 179
 - due to *Neisseria meningitidis*
 - case reviews for 25-year period, 87
 - fulminant, coagulopathy markers in, 643
 - due to nontyphoid *Salmonella*, age-related differences [letter and reply], 239
 - nosocomial
 - contaminants vs. true pathogens in [letter], 986
 - ocular lesions in, 306
 - in portosystemic shunt, 384
 - due to *Staphylococcus aureus*
 - aortic aneurysm in, 823
 - database on, 633
 - methicillin-resistant, pathogenic significance, 368
 - due to *Stentotrophomonas maltophilia*, in bone marrow transplantation, 195
 - due to *Streptococcus pneumoniae*
 - FcR111a-R131 allotype and, 25
 - penicillin-resistant, outcome, 520
 - serogroups in, vaccine implications, 122
- Bacteroides*, vaginal colonization, variation with menstrual cycle, 901
- Bacteroides* infections, bacteremia, prospective observational trial, 870
- Bananas, necrotizing fasciitis due to, e-mail hoax, April News and Events
- Bartonella
 - Coxiella burnetii* cross-reactivity with, 609
 - detection, 166
- Bartonella infections
 - in HIV infection, prophylaxis, S29
 - parapharyngeal abscess, 599
- Behavior modification, in opportunistic infection prevention, S15
- Bell's palsy, due to varicella-zoster virus, 529
- Biopsy, stereotactic, brain lesions, in HIV infection, 491
- Bioterrorism
 - challenges, 926
 - vaccination for, May News and Events, 843
- Bismuth therapy, for *Helicobacter pylori* infections, serologic evaluation after, 976
- Blastocystis hominis* infections, diarrhea, in Swedish adults, 770
- Blastomycosis
 - central nervous system, recurrent, 969
 - epidemiology, 582
 - molecular epidemiology, 328
 - practice guidelines, 679
- Blood cells, suppression, in HIV infection, 504
- BMS-232632, for HIV infection, S160
- Bone infections (see Osteomyelitis)
- Bone marrow
 - dysfunction, in HIV infection, 256
 - suppression, due to antiretroviral agents, S96
 - transplantation, *Stentotrophomonas maltophilia* bacteremia in, 195
- Book reviews
 - AIDS Therapy*, 815
 - Clinical Infectious Diseases: A Practical Approach*, 816
 - Current Clinical Topics in Infectious Diseases*, 817
 - Cytotoxic Lymphocytes: Basic Mechanisms and Medical Applications*, 934
 - Infectious Diseases*, 818
 - Management of Respiratory Tract Infections*, 935
 - Tropical Infectious Diseases: Principles, Pathogens, and Practice*, 816
- Bordetella*, detection, 166
- Bordetella bronchiseptica* infections, with cytomegalovirus infections, in malnutrition [letter], 408
- Bordetella* infections (see also Pertussis)
 - cough in, 387
- Borrelia burgdorferi*, detection, 166

- Borreliosis (see Lyme disease)
- Botulism, vaccination, 843
- Brain
- abscess
 - due to *Aspergillus*, practice guidelines, 696
 - due to *Salmonella typhimurium*, 621
 - due to *Streptococcus intermedius*, 396
 - borreliosis, treatment [letter], 237, 410
 - Coccidioides immitis* hyphal forms in, 349
 - encephalitis (see Encephalitis)
 - increased intracranial pressure on, in meningitis, due to *Cryptococcus neoformans*, 47
 - inflammation of (see Encephalitis)
 - lesions, in HIV infection, stereotactic biopsy, 491
 - meningeal inflammation (see Meningitis)
 - metronidazole effects on, 211
 - rabies virus infections, 4
 - tuberculoma, treatment, 625
 - tularemia effects on, 211
- Brain-stem, encephalitis, due to herpes simplex virus, herpes zoster oticus with, 229
- Bronchiectasis, in voluntary cough suppression, 572
- Bronchitis
- due to *Aspergillus*
 - in malaria, 938
 - practice guidelines, 696
 - treatment, with quinolones, 243
- Brucella* infections
- organism detection in, 166
 - vaccination, 843
- Burkholderia pseudomallei* infections, treatment [letter], 235
- Butoconazole, for candidiasis, practice guidelines, 662
- Calcium carbonate, for diarrhea, protease inhibitor-associated, 908
- Calicivirus infections, diarrhea, in Swedish adults, 770
- Campylobacter* infections, diarrhea in Swedish adults, 770
- Cancer
- funguria in, 14
 - hepatitis C in, treatment, in pediatric patients, 585
 - immunorestitution disease in, 882
 - Mycobacterium kansasii* infections in, 965
 - zygomycosis in, 851
- Candidemia, practice guidelines, 662
- Candidiasis
- disseminated, practice guidelines, 662
 - hepatosplenic, immunorestitution disease in, 882
 - in HIV infection
 - primary, in African women, 486
 - prophylaxis, S29
 - refractive, 749
 - prophylaxis, in neutropenia, 300
 - treatment
 - in HIV infection, failure, 749
 - practice guidelines, 662
 - urinary, in hospitalized patients, 14
- Candiduria, treatment, with fluconazole, 19
- Capnocytophaga granulosa* infections, abscess, 606
- Carriage (see Colonization)
- Catheter-related infections
- urinary, due to fungi, 14
 - vascular
 - in HIV infection, 949
 - due to methicillin-resistant *Staphylococcus aureus*, 322
 - due to *Methylobacterium mesophilicum*, 936
- Cats
- cat-scratch disease due to, parapharyngeal abscess in, 599
 - plague associated with, 893
- Cefotaxime, resistance to, *Streptococcus pneumoniae*, 71
- Ceftriaxone
- for neurosyphilis, in HIV infection, 540
 - for *Staphylococcus aureus* osteomyelitis, 205
- Cellulitis, epidemiology, in injection drug users, 579
- Centers for Disease Control and Prevention, budgeting practices, April News and Events
- Central nervous system infections (see also Brain)
- due to *Aspergillus*, practice guidelines, 696
 - due to *Blastomyces dermatitidis*, recurrent, 969
 - due to *Coccidioides immitis*, hyphal forms in, 349
 - due to *Cryptococcus neoformans*, practice guidelines, 710
 - due to *Histoplasma capsulatum*, 595, 688
 - due to *Pneumocystis carinii*, in HIV infection, treatment, 397
- Cephalosporins, for *Neisseria meningitidis* pneumonia, case reviews for 25-year period, 87
- Cerebellar ataxia, in tularemia, 211
- Cerebrospinal fluid
- Coccidioides immitis* hyphal forms in, 349
 - herpes simplex virus detection in, 176
 - HIV load in, vs. neurologic symptoms, 962
 - Mycoplasma pneumoniae* detection in [letter and reply], 405
- Chemotherapy
- aspergillosis in, 41
 - for leukemia, hepatic granuloma after, due to *Propionibacterium acnes*, 219
 - Mycobacterium bovis* infections in, from contaminated solutions, 356
- Chickenpox (see Varicella-zoster virus infections)
- Chlamydial infections, treatment, with quinolones, 243
- Chlamydia pneumoniae* infections
- aortic aneurysms in, 946
 - cough in, 387
 - meningoencephalitis, 209
- Chlamydia trachomatis* infections
- in military, 736, 742
 - screening for, with polymerase chain reaction [letter and reply], 406
- Chloramphenicol
- in pregnancy [letter], 237
 - resistance to, *Shigella*, 515
- Cholesterol, elevation, due to antiretroviral agents, S96
- Chorioretinitis, due to *Treponema pallidum*, 479
- Chronic granulomatous disease, liver abscess in, treatment with granulocyte-macrophage colony-stimulating factor, 222
- Cidofovir
- for cytomegalovirus retinitis, in HIV infection, 182
 - for progressive multifocal leukoencephalopathy [letter], 234
 - prophylactic, for opportunistic infections, S25
- Ciprofloxacin
- prophylactic, for opportunistic infections, S29
 - resistance to, *Klebsiella pneumoniae*, 473
 - state-of-the-art, 243
- Cirrhosis, liver, necrotizing fasciitis in, due to *Klebsiella pneumoniae* [letter], 989
- Clarithromycin
- for *Mycobacterium avium* complex infections, 288
 - prophylactic, for opportunistic infections, S25, S29

- Clostridium difficile*, colonization, in hospital ward, 952
Clostridium difficile infections
 diarrhea
 in rehabilitation unit, 425
 in Swedish adults, 770
 necrotizing fasciitis, 954
Clostridium infections, septic arthritis, 590
Clotrimazole, for candidiasis, practice guidelines, 662
Coagulopathy, in *Neisseria meningitidis* infections, markers for, 643
Coccidioidomycosis
 central nervous system, hyphal forms in, 349
 in HIV infection, prophylaxis, S29
 outbreak, 61
 peritonitis, 971
 practice guidelines, 658
 skin testing for, in California, 612
Cognitive dysfunction, due to antiretroviral agents, S96
Colonization
 Clostridium difficile, in hospital ward, 952
 epidemiology, in rehabilitation unit, 425
 Giardia lamblia, in infants, 419
 Klebsiella pneumoniae, drug-resistant, 55
 Streptococcus pneumoniae, penicillin-resistant, 191
 vaginal, variation with menstrual cycle, 901
Common cold, nasal fluid flow and pressures in, during blowing, sneezing, and coughing, 387
Computed tomography, of nasal fluid flow, during blowing, sneezing, and coughing, 387
Conjunctivitis, in West Nile virus infections, 413
Coronary artery bypass graft surgery, radial artery harvest site infections in, risk factors for, 270
Cotton-wool spots, in bacteremia, 306
Cough
 nasal fluid flow and pressures in, 387
 nonproductive, in military force population, causes, 534
 suppression, in *Mycobacterium avium* complex infections, 572
 in tuberculosis, population-based survey, 293
Coxiella burnetii infections
 outbreaks, 214
 vaccination, 843
Crohn's disease, treatment with metronidazole, psychiatric symptoms due to, 213
Cryptococcosis
 in HIV infection
 meningitis, 47
 prophylaxis, S29
 treatment of, 710
 immunorestitution disease in, 882
 practice guidelines, 710
Cryptosporidiosis
 diarrhea
 in Swedish adults, 770
 in HIV infection, prophylaxis, S29
Culture
 Bartonella, 166
 Bordetella, 166
 Borrelia burgdorferi, 166
 Brucella, 166
 fastidious bacteria, 166
 Francisella tularensis, 166
 Legionella, 166
 Leptospira, 166
Cutaneous larva migrans, treatment, 811
Cutaneous leishmaniasis, epidemiology, East Timor [letter], 840
Cyst(s), echinococcal, of spine, 442, 567
Cystocele, recurrent infections in, 152
Cytokines, as vaccine adjuvants, S266
Cytomegalovirus infections
 in HIV infection
 prophylaxis, S1, S15
 retinitis, 182, 231
 immunorestitution disease in, 882
 in malnutrition, with *Bordetella bronchiseptica* infections [letter], 408
 vaccination, in transplantation, 857
Cytoplasmic retinoic acid binding protein, inhibition, antiretroviral agents in, S135
Cytosine arabinoside, for progressive multifocal leukoencephalopathy [letter], 234
Dapsone, prophylactic, for opportunistic infections, S25, S29
Delavirdine, for HIV infection
 adverse effects, S96
 in drug combinations, S123, S130
 resistance to, S185
Dengue fever
 in HIV infection, HIV antibody testing in, 819
 outbreaks, March New and Events
Diabetes mellitus
 due to antiretroviral agents, S96, S135
 funguria in, 14
 necrotizing fasciitis in, due to *Klebsiella pneumoniae* [letter], 989
 radial artery harvest site infections in, 270
Dialysis, aortic aneurysm in, due to *Staphylococcus aureus*, in dialysis, 823
Diarrhea
 due to antiretroviral agents, S96
 due to *Clostridium difficile*, in rehabilitation unit, 425
 enteropathogen identification in, in Swedish adults, 770
 in HIV infection, primary, in African women, 486
 due to protease inhibitors, in HIV infection, 908
 due to protozoa, reporting practice guidelines for, 401
 requiring hospitalization, organisms causing, in pediatric patients, 953
Didanosine, for HIV infection
 adverse effects, S96
 in drug combinations, S123, S130, S143
 hydroxyurea with, S193
 resistance to, S185
Dideoxycytidine, for HIV infection, resistance to, S185
Diphenoxylate/atropine, for diarrhea, protease inhibitor-associated, 908
Diphtheria, vaccination, in transplantation, 857
Diskitis, due to *Peptostreptococcus micros*, 622
DNA vaccines, tuberculosis, S233, S283
 animal models, S283
 regulatory process for, S247
Doxycycline, for neuroborreliosis [letter], 237, 410
Drug abuse, injection
 abscess prevalence in, 579
 cellulitis prevalence in, 579
 endocarditis in, pathogenesis, 374
 opportunistic infection prophylaxis in, S29
Drug resistance (see also Susceptibility testing)
 Acinetobacter, 454
 ampicillin, *Shigella*, 515

- Bacteroides*, 870
 cefotaxime, *Streptococcus pneumoniae*, 71
 chloramphenicol, *Shigella*, 515
 ciprofloxacin, *Klebsiella pneumoniae*, 473
 enterococci
 aminoglycosides, 799
 vancomycin (see Enterococcal infections, vancomycin-resistant)
 epidemiology, in rehabilitation unit, 425
 gram-positive organisms, linezolid for, 146
 human immunodeficiency virus, S177
 test methods for, S117
Klebsiella pneumoniae, 55
 ciprofloxacin, 473
 mechanisms, difficult-to-detect, 799
 methicillin, *Staphylococcus aureus* (see *Staphylococcus aureus* infections, methicillin-resistant)
 multiple
 HIV, S185
 Klebsiella pneumoniae, 55
 linezolid for, 146
 Mycobacterium tuberculosis, 617
 Shigella, 515
Neisseria meningitidis, in 1997, 212
 penicillin, *Streptococcus pneumoniae*, 78, 191, 454, 520
Pseudomonas aeruginosa, 454
 quinolones, 243, 454
 SENTRY surveillance program, 454
Shigella, 515
Staphylococcus aureus
 methicillin (see *Staphylococcus aureus* infections, methicillin-resistant)
 vancomycin, 799
Streptococcus pneumoniae
 cefotaxime, 71
 penicillin, 78, 191, 520
 surveillance for, 454
 streptomycin, *Shigella*, 515
 sulfisoxazole, *Shigella*, 515
 tetracycline, *Shigella*, 515
 trimethoprim-sulfamethoxazole, *Shigella*, 515
 vancomycin
 enterococci (see Enterococcal infections, vancomycin-resistant)
 Staphylococcus aureus, 799
 Duke criteria, for endocarditis diagnosis, proposed modifications, 633
 Dyslipidemia, due to antiretroviral agents, S96
 Dyspepsia, due to antiretroviral agents, S96
 Ear infections
 due to *Aspergillus*, practice guidelines, 696
 due to *Mycobacterium tuberculosis*, treatment, paradoxical reaction in, 625
 Echinococcal cyst, spinal, 442, 567
 Echocardiography, in endocarditis, accuracy of, 825
 Economic issues
 Centers for Disease Control and Prevention budgeting practices, April News and Events
 in home intravenous antibiotic program, 639
 Editorial, 1
 Education
 on HIV transmission prevention, in military, 730
 on opportunistic infections in HIV infection, S15
 on raw meat irradiation, March News and Events
 on *Streptococcus pneumoniae* vaccination, April News and Events
 Efavirenz, for HIV infection, 313
 adverse effects, S96
 in drug combinations, S123
 hypersensitivity to, 227
 resistance to, S185
 Elderly persons, infectious disease in, 931
 ELISA (enzyme-linked immunosorbent assay), for Lyme disease, 545
 E-mail hoax, on bananas and necrotizing fasciitis, April News and Events
 Encephalitis
 due to *Chlamydia pneumoniae*, 209
 due to herpes simplex virus
 herpes zoster oticus with, 229
 treatment, 185
 vaccination, 549
 tick-borne, isolated initial phase [letter], 987
 due to Tonate virus, 188
 due to *Toxoplasma gondii*, in HIV infection, prophylaxis, S15, 602
 Venezuelan equine, vaccination, 843
 due to Venezuelan equine encephalitis complex, 188
 due to West Nile virus, 413
 Endocarditis
 due to *Aspergillus*, practice guidelines, 696
 in bicuspid aortic valve, 336
 due to *Candida*, practice guidelines, 662
 due to *Coxiella burnetii*, *Bartonella* cross-reactivity in, 609
 diagnosis, Duke criteria for, proposed modifications, 633
 echocardiography in, accuracy of, 825
 due to *Francisella tularensis*, 399
 due to β -hemolytic streptococci, mortality in, 624
 due to *Mycobacterium fortuitum*, 605, 629
 due to *Propionibacterium acnes*, in liver transplantation, 224
 right-side, in injection drug users, pathogenesis, 374
 due to *Saksenaea vasiformis*, 942
 Endophthalmitis, due to *Candida*, practice guidelines, 662
 Entamoeba infections, in HIV infection, epidemiology, 955, 959
 Enterobacter cloacae infections, bacteremia, nosocomial, 35
 Enterobacteriaceae, susceptibility testing, 799
 Enterococcal infections
 resistance in, aminoglycosides, 799
 vancomycin-resistant, 403
 bacteremia, mortality in, 466
 surveillance for, 454
 susceptibility testing, 799
 treatment
 with linezolid, 146
 with quinupristin/dalfopristin, 790
 Enterococcus faecalis infections, bacteremia, after portosystemic shunt placement, 384
 Enterococcus faecium infections
 bacteremia, antibiotic susceptibility surveillance, 454
 vancomycin-resistant
 bacteremia, treatment with linezolid, 403
 mortality in, 466
 treatment, with quinupristin/dalfopristin, 790
 Enterotoxin, staphylococcal, vaccination, 843
 Enterovirus 71 infections, treatment [letter], 988
 Environmental exposures, to opportunistic infections, prophylaxis, S29
 Epidemics, tuberculosis, control with vaccines, S316
 Epidemiology (see also Outbreaks)
 abscesses, in injection drug users, 579
 aging, infectious disease and, 931

- blastomycosis, 582
 - organism diversity, 328
- cellulitis, in injection drug users, 579
- Chlamydia trachomatis* infections, in military, 736, 742
- Clostridium difficile*, in hospital ward, 952
- Coccidioides immitis* infections, in returned travelers, 61
- Coccidioides immitis*-positive skin tests, in California, 612
- dengue fever, March New and Events
- Entamoeba* infections, in HIV infection, 955, 959
- GB virus C/hepatitis G virus infections, in pediatric patients, 569
- group B streptococcal infections in, maternal and neonatal, 276
- helminth infections, in HIV infection [letter], 241
- influenza, March New and Events
- Klebsiella pneumoniae* infections, multidrug-resistant, 55
- Neisseria gonorrhoeae* infections, in military, 736, 742
- nosocomial infections in rehabilitation unit, 425
- sporotrichosis, Peru, 65
- Streptococcus pneumoniae*
 - serogroups for vaccines, 100, 122
 - serotype 1, 319
- tuberculosis, S233
- West Nile virus infections, 413
- Epstein-Barr virus, detection in lymphoma, after kidney transplantation, 576
- Epstein-Barr virus infections
 - prophylaxis, in HIV infection, 757, 762
 - vaccination, in transplantation, 857
- Equine encephalitis complex, Venezuelan, tonate virus subtype of, 188
- Errata
 - cat-scratch disease (2000;30:599), 841
 - influenza vaccination (2000;30:342), 992
 - Neisseria* vaccine (1999;29:1295), 632
 - rifabutin use with protease inhibitors (2000;30:779), 992
 - West Nile virus outbreak (2000;30:413), 841
- Erythromycin, for pertussis, February News and Events
- ESAT-6 antigen, *Mycobacterium tuberculosis*, T lymphocyte recognition, S201
- Escherichia coli* infections
 - bacteremia, antibiotic susceptibility surveillance, 454
 - enteroaggregative, diarrhea, in Swedish adults, 770
 - enterotoxigenic, diarrhea
 - in Swedish adults, 770
 - hemolytic-uremic syndrome in [letter and reply], 984
 - in rehabilitation unit, 425
 - urinary tract, Shiga toxin-producing, hemolytic-uremic syndrome in, 395
- Esophageal infections, due to *Candida*, practice guidelines, 662
- Ethambutol
 - for *Mycobacterium avium* complex infections, 288
 - for *Mycobacterium terrae* infections, 444
 - prophylactic, for opportunistic infections, S25
- Ethical issues, in tuberculosis vaccine trials, S271
- Exophiala jeikei* infections, prophylaxis, in neutropenia, 300
- Eye disorders, in bacteremia, 306
- Eye infections
 - due to *Aspergillus*, practice guidelines, 696
 - due to *Candida*, practice guidelines, 662
 - due to herpes simplex virus, 549
 - due to *Treponema pallidum*, 479
- Facial nerve
 - herpes zoster, with herpes simplex virus encephalitis, 229
 - palsy, due to varicella-zoster virus, 529
- Facultative bacteria, susceptibility testing, 799
- Famciclovir, prophylactic, for opportunistic infections, S29
- Fasciitis, necrotizing (*see* Necrotizing fasciitis)
- Fat, maldistribution, due to antiretroviral agents, S96, S135
- Fat graft, necrosis, lipoid meningitis in, 613
- Fatigue, due to antiretroviral agents, S96
- Fc,RIIIa-R131 allotypes, in *Streptococcus pneumoniae* pneumonia severity, 25
- Fever
 - in critical illness, evaluation [letter], 234
- dengue
 - in HIV infection, HIV antibody testing in, 819
 - outbreaks, March New and Events
- in histoplasmosis, 595
- in HIV infection, primary, in African women, 486
- in neutropenia, treatment, with quinolones, 243
- Q
 - endocarditis in, *Bartonella* cross-reactivity in, 609
 - outbreaks, 214
 - vaccination, 843
- rabbit (*see* Tularemia)
- in tuberculosis, population-based survey, 293
- in West Nile virus infections, 413
- Filgrastim, in neutropenia, in HIV infection, 256
- Fluconazole
 - for blastomycosis, 679
 - for candidiasis
 - in HIV infection, failure, 749
 - practice guidelines, 662
 - for candiduria, 19
 - for coccidioidomycosis, 658, 971
 - for cryptococcosis, 710
 - practice guidelines for, 653
 - for histoplasmosis, 688
 - prophylactic, for opportunistic infections, S25, S29
 - for sporotrichosis, 684
 - for urinary tract infections, 14
- Flucytosine
 - for candidiasis, practice guidelines, 662
 - for cryptococcosis, 710
 - practice guidelines for, 653
 - for meningitis, due to *Cryptococcus neoformans*, in HIV infection, 47
- Fluoroquinolones, state-of-the-art, 243
- Food, antiretroviral agent interactions with, S96
- Foodborne diseases
 - in HIV infection, prophylaxis, S29
 - raw meat irradiation and, patient education on, March News and Events
- Foscarnet, prophylactic
 - for lymphoma, in HIV infection, 757, 762
 - for opportunistic infections, S25, S72
- Francisella tularensis*, detection, 166
- Francisella tularensis* infections
 - ataxia in, 211
 - endocarditis, 399
 - vaccination, 843
- Fungal infections (*see also specific fungi*)
 - in HIV infection, prophylaxis, S1, S15
 - practice guidelines for (*see under* Infectious Diseases Society of America, practice guidelines)
 - prophylaxis, in neutropenia, 300
- Funguria, surveillance, 14

- Gallbladder infections, due to *Candida*, practice guidelines, 662
- Ganciclovir, prophylactic
for lymphoma, in HIV infection, 757, 762
for opportunistic infections, S25, S29, S72
- Gangrene, due to *Clostridium difficile*, 954
- Gastrointestinal infections (see also Diarrhea)
in HIV infection, prophylaxis, S29
inflammatory pseudotumor formation in, in HIV infection, 826
due to *Mycobacterium avium* complex, in heart transplantation, 603
- GB virus C/hepatitis G virus infections, epidemiology, in pediatric patients, 569
- Gemella morbillorum* infections, bacteremia, after portosystemic shunt placement, 384
- Genital infections
due to *Candida*, practice guidelines, 662
due to herpes simplex virus
amniotic fluid viral load in, 363
vaccination, 549
viral shedding in, 261, 268
susceptibility to, menstrual cycle and, 901
- Gentamicin
extended-interval dosing, national survey, 433, 440
for *Francisella tularensis* endocarditis, 399
- Giardia intestinalis* infections, diarrhea, in Swedish adults, 770
- Giardia lamblia*, carriage, in infants, 419
- Gingivostomatitis, due to herpes simplex virus, vaccination, 549
- Glucose intolerance, due to antiretroviral agents, S96
- Gonorrhea (see *Neisseria gonorrhoeae* infections)
- Gram-positive infections, resistance in, treatment with linezolid, 146
- Granulocyte colony-stimulating factor, in neutropenia, in HIV infection, 256
- Granulocyte-macrophage colony-stimulating factor
with influenza vaccination, in stem-cell transplantation, 342
for liver abscess, due to *Staphylococcus aureus*, in chronic granulomatous disease, 222
- Granuloma, hepatic, due to *Propionibacterium acnes*, 219
- Granulomatous disease, due to *Leishmania donovani*, 764
- Grepafloxacin, state-of-the-art, 243
- Growth, *Giardia lamblia* colonization effects on, 419
- HAART (see Highly active antiretroviral therapy)
- Haemophilus*, susceptibility testing, 799
- Haemophilus aphrophilus* infections, lymphadenitis in, 627
- Haemophilus influenzae* infections
pneumonia, in HIV infection, 461
vaccination
in transplantation, 857
trial design, S206
- Handwashing, vs. hand disinfection [letter], 990
- Headache
due to antiretroviral agents, S96
in HIV infection, primary, in African women, 486
in West Nile virus infections, 413
- Heart
endocarditis (see Endocarditis)
transplantation, *Mycobacterium avium* complex intestinal infections in, 603
valvular disease, endocarditis in, 336
- Helicobacter pylori* infections, treatment, serologic evaluation, 976
- Helminth infections, in HIV infection, epidemiology [letter], 241
- Hemolytic-uremic syndrome
due to *Escherichia coli* [letter and reply], 984
in *Escherichia coli* infections, Shiga toxin-producing, 395
- Hemoptysis, in tuberculosis, population-based survey, 293
- Hepatitis, due to trovafloxacin, 400
- Hepatitis A
in HIV infection, prophylaxis, S15, S29
vaccination, in transplantation, 857
- Hepatitis B
in HIV infection, prophylaxis, S15, S29
immunorestitution disease in, 882
vaccination, in transplantation, 857
- Hepatitis C
in health care workers, May News and Events
in HIV infection, S77
prophylaxis, S1, S29
survival effects [letter and reply], 409
treatment, in pediatric patients, 585
- Hepatitis E, in California, 618
- Hepatitis G, epidemiology, in pediatric patients, 569
- Hepatosplenic candidiasis, practice guidelines, 662
- Herpes simplex virus infections
encephalitis
herpes zoster oticus with, 229
treatment, exacerbation after, 185
in HIV infection, prophylaxis, S1, S29
meningitis, immunogenetic determinants, 176
peritonitis [letter], 839
type 2
amniotic fluid viral load in, 363
viral shedding in, in homosexual men, 261, 268
urethritis, screening for, 982
vaccination
review article, 549
in transplantation, 857
- Herpes zoster, facial palsy in, 529
- Herpes zoster oticus, with herpes simplex virus encephalitis, 229
- Highly active antiretroviral therapy, for HIV infection
adherence to, S96, S171
adverse effects, S96
immunorestitution disease in, 882
incomplete response to [letter], 407
with JC virus infection, 95
Mycobacterium avium complex infection recurrence after, 511
opportunistic infection prevention in (see Opportunistic infections, in HIV infection, prevention)
resistance to, S185
toxoplasmosis prophylaxis discontinuation in, 602
in tuberculosis, 779
- Histoplasmosis
in HIV infection
prophylaxis, S29
severe, 877
practice guidelines, 688
prostate involvement in, 595
- HIV infection (see Human immunodeficiency virus infection)
- Hodgkin's disease, immunorestitution disease in, 882
- Home-care programs, for intravenous antibiotics, managed care financial impact, 639
- Homosexual persons, herpes simplex virus type 2 shedding in, 261, 268
- Hookworm disease, larva migrans in, treatment, 811
- Human herpesvirus 8 infections, in HIV infection, S72
prophylaxis, S1
without Kaposi's sarcoma development, 221

- Human immunodeficiency virus, mutation, S185
- Human immunodeficiency virus infection
- Bartonella* infections in, prophylaxis, S29
 - brain lesions in, stereotactic biopsy, 491
 - candidiasis in
 - prophylaxis, S29
 - refractive, 749
 - catheter infections in, 949
 - central nervous system infections in, due to *Pneumocystis carinii*, treatment, 397
 - coccidioidomycosis in, prophylaxis, S29
 - cryptococcosis in
 - meningitis, 47
 - prophylaxis, S29
 - treatment of, 710
 - cryptosporidiosis in, prophylaxis, S29
 - cytomegalovirus infections in
 - prophylaxis, S1, S15, S29
 - retinitis
 - natural history, 231
 - treatment, 182
 - dengue fever in, HIV antibody testing in, 819
 - diagnosis, early, S15
 - encephalitis in, due to *Toxoplasma gondii*, prophylaxis, 602
 - Entamoeba* infections in, epidemiology, 955, 959
 - foodborne diseases in, prophylaxis, S29
 - fungal infections in, prophylaxis, S1, S15
 - gastrointestinal infections in, prophylaxis, S29
 - Haemophilus influenzae* pneumonia in, 461
 - helminth infections in, epidemiology [letter], 241
 - hepatitis A in, prophylaxis, S15, S29
 - hepatitis B in, prophylaxis, S15, S29
 - hepatitis C in, S77
 - prophylaxis, S1, S29
 - survival effects [letter and reply], 409
 - herpes simplex virus infections in, prophylaxis, S1, S29
 - histoplasmosis in
 - practice guidelines, 688
 - prophylaxis, S29
 - severe, 877
 - human herpesvirus 8 infections in, S72
 - prophylaxis, S1
 - human herpesvirus 8 seropositivity in, without Kaposi's sarcoma development, 221
 - human papillomavirus infections in, prophylaxis, S29
 - immunorestitution disease in, 882
 - inflammatory pseudotumor in, resembling lymphoma, 826
 - influenza in, prophylaxis, S15, S29
 - JC virus infections in, treatment, 95
 - Kaposi's sarcoma in, S72
 - prophylaxis, S1
 - lymphoepithelial parotid lesions in, malignant transformation, 947
 - lymphoma in, 491, 947
 - prevention with acyclovir, 757, 762
 - malaria in, HIV antibody testing in, 819
 - meningitis in, due to *Cryptococcus neoformans*, 47
 - Mycobacterium avium* complex infections in
 - prophylaxis, S1, S15, S29, S66
 - recurrence after therapy, 511
 - Mycobacterium terrae* infections in, 831
 - neurologic disorders in, vs. cerebrospinal fluid viral load, 962
 - neurosyphilis in, treatment, 540
 - neutropenia in, 256
 - opportunistic infections in (see Opportunistic infections, in HIV infection; specific infections)
 - Pneumocystis carinii* infections in
 - central nervous system, treatment, 397
 - pneumonia, diagnosis, 141
 - prophylaxis, S1, S15, S29, S66
 - pneumonia in
 - due to *Haemophilus influenzae*, 461
 - due to *Pneumocystis carinii*, diagnosis, 141
 - in pregnancy, opportunistic infection prophylaxis in, S15
 - primary
 - clinical features, in African women, 486
 - neurologic disorders in, vs. cerebrospinal fluid viral load, 962
 - resistance in, S177
 - test methods for, S117
 - respiratory infections in, prophylaxis, S1, S15, S29
 - retinitis in, due to cytomegalovirus
 - natural history, 231
 - treatment, 182
 - Salmonella* infections in, prophylaxis, S29
 - sexually transmitted diseases in, prophylaxis, S29
 - splenomegaly in, 943
 - sporotrichosis in, practice guidelines, 684
 - Streptococcus pneumoniae* infections in, prophylaxis, S15, S29
 - syphilis in, treatment, 540
 - testing for
 - in dengue infections, 819
 - in malaria, 819
 - T lymphocytes in
 - hydroxyurea effects on, S193
 - opportunistic infection prevention based on, S15
 - opportunistic infection prophylaxis discontinuation and, S66
 - treatment response and, S177, 504
 - vs. viral load, during antiretroviral therapy, 392
 - toxoplasmosis in
 - encephalitis, prophylaxis, 602
 - prophylaxis, S29
 - transmission
 - prevention, in military, 730
 - risk behavior for, in military, 723, 730
 - travelers' diseases in, prophylaxis, S29
 - treatment
 - with antiretroviral agents (see Antiretroviral agents, for HIV infection; Highly active antiretroviral therapy; specific drugs)
 - with combination therapy, 313
 - failure, S177
 - combination therapy for, 313
 - hematosuppression reversal in, 504
 - incomplete response to [letter], 407
 - JC virus infections with, 95
 - low-level viral replication during, 392
 - protease inhibitor-associated diarrhea in, 908
 - salvage, S160, S177
 - T lymphocyte response in, S177, 504
 - tuberculosis in
 - prophylaxis, S1, S15, S29
 - treatment with rifabutin, 779
 - vaccines for, S247, S309
 - vaccination in
 - for opportunistic infections, S29
 - rabies, 218
 - with transplantation, 857

- varicella-zoster infections in, prophylaxis, S1, S29
- viral load in
 - vs. neurologic status, 962
 - vs. T lymphocyte count, during antiretroviral therapy, 392
- treatment strategy and, S177
- waterborne diseases in, prophylaxis, S29
- Human papillomavirus infections, in HIV infection, prophylaxis, S29
- Hydatid cyst, of spine, 442, 567
- Hydroxyurea, for HIV infection, S143, S193
 - adverse effects, S96
 - in drug combinations, S123
- Hypercholesterolemia, due to antiretroviral agents, S96
- Hyperglycemia, due to antiretroviral agents, S96, S135
- Hyperlipidemia, due to antiretroviral agents, S135
- Hypersensitivity reaction
 - to antiretroviral agents, S96
 - to efavirenz, 227
 - purified protein derivative, mucosal tuberculosis vaccination effects on, S217
- Hypertension, indinavir-induced, 619
- Hyperthermia, malignant, in critical illness, evaluation [letter], 234
- Hypertriglyceridemia, due to antiretroviral agents, S96
- Immunization (see Vaccines and vaccination)
- Immunoblot assay, for Lyme disease, 545
- Immunodeficiency (see also Chemotherapy; Human immunodeficiency virus infection; Neutropenia; Transplantation)
 - bacille Calmette-Guérin vaccination in, ethical issues, S271
 - Blastomyces dermatitidis* infections in, practice guidelines, 679
 - in chronic granulomatous disease, liver abscess in, treatment with granulocyte-macrophage colony-stimulating factor, 222
 - in HIV infection, reversal by treatment, 504
 - immunorestitution disease in, 882
- Immunorestitution disease, immune response in, 882
- Incontinence, urinary, recurrent infections in, 152
- Indinavir, for HIV infection, S160
 - adverse effects, S96, S135
 - in drug combinations, S123, S160
 - pharmacodynamics, S151
 - side effects, 619
- Infants (see Pediatric patients)
- Infection control, hand disinfection in [letter], 990
- Infectious Diseases Society of America
 - opportunistic infection prevention practice guidelines (see Opportunistic infections, in HIV infection, prevention)
- practice guidelines, fungal infection treatment, 652
 - due to *Aspergillus*, 696
 - due to *Blastomyces dermatitidis*, 679
 - due to *Candida*, 662
 - due to *Coccidioides immitis*, 658
 - due to *Cryptococcus neoformans*, 710
 - drugs for, 653
 - due to *Histoplasma capsulatum*, 688
 - due to *Sporothrix schenckii*, 684
- Inflammatory bowel disease, treatment with metronidazole, psychiatric symptoms due to, 213
- Influenza
 - epidemiology, March News and Events
 - in HIV infection, prophylaxis, S15, S29
 - prophylaxis, zanamivir for, 587
 - Streptococcus pneumoniae* pneumonia and, 784
 - vaccination
 - in stem-cell transplantation, granulocyte-macrophage colony-stimulating factor with, 342
 - in transplantation, 857
- Insulin resistance, due to antiretroviral agents, S135
- Interferon- α
 - for enterovirus 71 infections [letter], 988
 - for hepatitis C
 - in HIV infection, S77
 - in pediatric patients, 585
- Interferon- γ , response
 - to mucosal bacille Calmette-Guérin vaccination, S217
 - to *Mycobacterium tuberculosis* ESAT-6 antigen exposure, S201
- Interleukin-6, measurement, in fulminant *Neisseria meningitidis* infections, 643
- Intracranial pressure, increased, in meningitis, due to *Cryptococcus neoformans*, 47
- Irradiation, of raw meat, patient education on, March News and Events
- Isoniazid
 - prophylactic, for tuberculosis, S25, S29
 - with rifalazil, for tuberculosis, animal model, S288
- Itraconazole
 - for aspergillosis, 696
 - for blastomycosis, 679
 - for candidiasis, practice guidelines, 662
 - for coccidioidomycosis, 658
 - for cryptococcosis, 710
 - practice guidelines for, 653
 - for histoplasmosis, 688
 - prophylactic
 - for neutropenia, 300
 - for opportunistic infections, S25, S29
 - for sporotrichosis, 684
- Ivermectin, for cutaneous larva migrans, 811
- JC virus infections
 - in HIV infection
 - brain biopsy in, 491
 - treatment, 95
 - treatment [letter], 234
- Joint infections
 - due to *Candida*, practice guidelines, 662
 - due to *Clostridium*, 590
 - due to *Sporothrix schenckii*, practice guidelines, 684
- Kallikrein-kinin system activation, in streptococcal toxic shock syndrome, 961
- Kaposi's sarcoma
 - failure to develop, in human herpesvirus 8 seropositivity, 221
 - in HIV infection, S72
 - prophylaxis, S1
- Keratitis, due to herpes simplex virus, vaccination, 549
- Ketoconazole
 - for blastomycosis, 679
 - for candidiasis, practice guidelines, 662
 - for coccidioidomycosis, 658
 - practice guidelines for, 653
 - for histoplasmosis, 688
 - for sporotrichosis, 684
- Kidney
 - atrophy, indinavir-induced, 619
 - failure, in histoplasmosis, 595
 - stones, due to antiretroviral agents, S96
 - transplantation, lymphoma after, Epstein-Barr virus detection in, 576
- Klebsiella pneumoniae* infections

- bacteremia
 - antibiotic susceptibility surveillance, 454
 - ciprofloxacin-resistant, 473
 - necrotizing fasciitis [letter], 989
 - resistance in, 55, 473
 - susceptibility testing, 799
- KRM-1648 (rifalazil), for tuberculosis, animal model, S288
- β -Lactamases
 - detection, 799
 - Klebsiella pneumoniae*, 473
- Lactic acidosis, due to stavudine, 198
- Lactobacillus*, vaginal colonization, variation with menstrual cycle, 901
- Lactobacillus acidophilus* infections, bacteremia, after portosystemic shunt placement, 384
- Lady Windermere syndrome, in *Mycobacterium avium* complex infections, 572
- Lamivudine, for HIV infection
 - adverse effects, S96
 - in drug combinations, S123, S130, S143, S160
 - hydroxyurea with, S193
 - resistance to, S185
- Larva migrans, cutaneous, treatment, 811
- Laryngeal infections
 - due to *Aspergillus*, practice guidelines, 696
 - due to *Candida*, practice guidelines, 662
- Legionella*, detection, 166
- Legionella dumoffii* infections, pneumonia, organism detection in, 382
- Leishmania chagasi* infections, natural history, in Brazil, 608
- Leishmaniasis
 - cutaneous, epidemiology, East Timor [letter], 840
 - mediastinal, 764
- Leptospira*, detection, 166
- Leukemia
 - hepatic granuloma in, due to *Propionibacterium acnes*, 219
 - hepatitis C in, treatment, in pediatric patients, 585
 - immunorestitution disease in, 882
 - zygomycosis in, 851
- Leukoencephalopathy, progressive multifocal
 - in HIV infection
 - brain biopsy in, 491
 - treatment, 95
 - treatment [letter], 234
- Levofloxacin
 - for *Rhodococcus equi* meningitis, 223
 - state-of-the-art, 243
- Linezolid
 - for *Enterococcus faecium* infections, vancomycin-resistant, 403
 - for multidrug-resistant infections, 146
- Lipodystrophy syndrome, due to antiretroviral agents, S135
- Lipoid meningitis, after autologous fat graft necrosis, 613
- Liver
 - abscess, due to *Staphylococcus aureus*, in chronic granulomatous disease, treatment with granulocyte-macrophage colony-stimulating factor, 222
 - cirrhosis, necrotizing fasciitis in, due to *Klebsiella pneumoniae* [letter], 989
 - enzyme profiles, in antiretroviral therapy, S96
 - granuloma, due to *Propionibacterium acnes*, 219
 - transplantation
 - endocarditis in, due to *Propionibacterium acnes*, 224
 - Scopulariopsis brevicaulis* infections in, 820
 - Staphylococcus aureus* infections in, methicillin-resistant, 322
 - trovafoxacin effects on, 400
- Loperamide, for diarrhea, protease inhibitor-associated, 908
- Low-density lipoprotein-receptor-related protein, inhibition, antiretroviral agents in, S135
- Lumbosacral plexopathy, in tuberculosis, 116
- Lyme disease
 - organism detection in, 166
 - serological testing methods, 545
 - treatment [letter], 237, 410
 - vaccination, May News and Events
 - in transplantation, 857
- Lymphadenitis
 - due to *Aspergillus*, practice guidelines, 696
 - due to *Haemophilus aphrophilus*, 627
 - due to *Mycobacterium bohemium*, 210
- Lymphadenopathy
 - in HIV infection, primary, in African women, 486
 - in mycobacterial infections, 29
 - due to *Sporothrix schenckii*, practice guidelines, 684
 - in West Nile virus infections, 413
- Lymphoepithelial lesions, parotid gland, malignant transformation, in HIV infection, 947
- Lymphoma
 - in HIV infection, 491, 947
 - inflammatory pseudotumor resembling, 826
 - prevention with acyclovir, 757, 762
 - immunorestitution disease in, 882
 - in kidney transplantation, Epstein-Barr virus detection in, 576
- Malaria
 - aspergillosis with, 938, 940
 - in HIV infection, HIV antibody testing in, 819
 - neurologic disorders in, causes [letter], 836
- Malignant hyperthermia, in critical illness, evaluation [letter], 234
- Malnutrition
 - cytomegalovirus infections in, with *Bordetella bronchiseptica* infections [letter], 408
 - Streptococcus pneumoniae* infections in, 319
- Managed care, home intravenous antibiotic program financial impact, 639
- Measles, vaccination, in transplantation, 857
- Mediastinitis
 - due to *Candida*, practice guidelines, 662
 - due to *Histoplasma capsulatum*, practice guidelines, 688
 - due to *Leishmania donovani*, 764
- Melioidosis, treatment [letter], 235
- Meningitis
 - due to *Aspergillus*, practice guidelines, 696
 - due to *Candida*, practice guidelines, 662
 - due to *Coccidioides immitis*, practice guidelines, 658
 - due to *Cryptococcus neoformans*, practice guidelines, 710
 - due to herpes simplex virus, immunogenetic determinants, 176
 - due to *Histoplasma capsulatum*, practice guidelines, 688
 - lipoid, after autologous fat graft necrosis, 613
 - Mollaret's, immunogenetic determinants, 176
 - due to *Neisseria meningitidis*, resistance in, 212
 - due to *Neisseria subflava*, 615
 - due to *Peptostreptococcus micros*, 622
 - postoperative, diagnosis [letter and reply], 836
 - due to *Pseudallescheria boydii*, treatment with voriconazole, 981
 - due to *Rhodococcus equi*, treatment, 223
 - due to *Sporothrix schenckii*, practice guidelines, 684
 - due to *Streptococcus intermedius*, 396

- due to *Streptococcus pneumoniae* penicillin-resistant, 78
 - serogroups in, vaccine implications, 122
 - due to viridans streptococci [letter and reply], 238
- Meningococcal infections (see *Neisseria meningitidis* infections)
- Meningoencephalitis, due to *Chlamydia pneumoniae*, 209
- Menstrual cycle, vaginal condition variation in, 901
- Methicillin, resistance to, *Staphylococcus aureus* (see *Staphylococcus aureus* infections, methicillin-resistant)
- Methylobacterium mesophilicum* infections, catheter-related, case report, 936
- Metronidazole, for Crohn's disease, psychiatric symptoms due to, 213
- Microbiology update
 - fastidious bacteria, 166
 - susceptibility testing, 798, 799
- Military forces
 - cough illness causes in, 534
 - sexually transmitted diseases in
 - chlamydial infections, 742
 - gonorrhea, 742
 - historical background, 719
 - prevention of, 730
 - risk behavior and, 723, 730
 - urethritis in, 736
 - Streptococcus pneumoniae* vaccination in, 157
- Minocycline, for neuroborreliosis [letter], 237, 410
- Mollaret's meningitis, immunogenetic determinants, 176
- Moraxella osloensis* infections, bacteremia, 179
- Mortality
 - Bacteroides* infections, 870
 - endocarditis, in bicuspid aortic valve, 336
 - Enterococcus faecium* bacteremia, vancomycin-resistant, 466
 - funguria, 14
 - β -hemolytic streptococcal endocarditis, 624
 - histoplasmosis, in HIV infection, 877
 - HIV infection, with hepatitis C [letter and reply], 409
 - methicillin-resistant *Staphylococcus aureus* infections, 322, 368
 - plague, cat-associated, 893
 - Saksenaea vasiformis* infections, 942
 - stereotactic brain biopsy, in HIV infection, 491
 - sudden infant death syndrome, due to *Pneumocystis carinii* [letter], 991
- Mucormycosis, due to *Saksenaea vasiformis*, 942
- Mucosal vaccination, tuberculosis, purified protein derivative hypersensitivity response to, S217
- Mucositis, in bone marrow transplantation, *Stentotrophomonas maltophilia* infections in, 195
- Multidrug resistance (see Drug resistance, multiple)
- Multiple myeloma, aspergillosis in, 41
- Mumps, vaccination, in transplantation, 857
- Myalgia
 - due to antiretroviral agents, S96
 - in HIV infection, primary, in African women, 486
 - in West Nile virus infections, 413
- Mycobacterial infections
 - immunorestitution disease in, 882
 - nontuberculous, lymphadenopathy in, 29
- Mycobacterium*, nontuberculous, tuberculosis vaccination and, S262
- Mycobacterium avium* complex infections
 - in HIV infection
 - prophylaxis, S1, S15, S29, S66
 - recurrence after therapy, 511
 - immunorestitution disease in, 882
 - intestinal, in heart transplantation, 603
 - treatment, with clarithromycin-including regimens, 288
- Mycobacterium bohemicum* infections, lymphadenitis in, 210
- Mycobacterium bovis*
 - aerosol challenge, in bacille Calmette-Guérin vaccination evaluation, S299
 - MPB83 antigen, in vaccines, S283
 - strain BCG (See Bacille Calmette-Guérin)
- Mycobacterium bovis* infections
 - vs. bacille Calmette-Guérin vaccination, S291
 - from chemotherapy solution contamination, 356
 - transmission to humans, S291
- Mycobacterium fortuitum* infections, endocarditis, 605
 - treatment, 629
- Mycobacterium kansasii* infections, in cancer, 965
- Mycobacterium terrae* infections
 - case reports and literature review, 444
 - in HIV infection, 831
- Mycobacterium tuberculosis* (see also Tuberculosis)
 - aerosol challenge, in bacille Calmette-Guérin vaccination evaluation, S299
 - antigens
 - for immunologic diagnosis, S243
 - in vaccine development, S254
 - ESAT-6 antigen, T lymphocyte recognition, S201
 - genome sequence, vaccine development and, S254
 - identification, for vaccine trials, S276
 - interferon- γ response to, S279
- Mycobacterium vaccae*, inactivated, for tuberculosis vaccination, in HIV infection, S309
- Mycoplasma pneumoniae* infections
 - cough in, 387
 - organism detection in [letter and reply], 405
- Mycotic aneurysm
 - due to *Chlamydia pneumoniae*, 946
 - due to *Staphylococcus aureus*, in dialysis, 823
- Myelitis
 - due to *Mycoplasma pneumoniae*, organism detection in [letter and reply], 405
 - in tuberculosis, 915
- Myocarditis, due to *Aspergillus*, practice guidelines, 696
- Nail disorders, due to *Candida*, practice guidelines, 662
- Nausea, due to antiretroviral agents, S96
- Neck, lymphadenitis
 - due to *Haemophilus aphrophilus*, 627
 - due to *Mycobacterium bohemicum*, 210
- Necrotizing fasciitis
 - due to bananas, e-mail hoax, April News and Events
 - due to *Clostridium difficile*, 954
 - due to *Klebsiella pneumoniae* [letter], 989
- Neisseria gonorrhoeae* infections
 - in military, 736, 742
 - susceptibility testing, 799
 - treatment, with quinolones, 243
- Neisseria meningitidis* infections
 - bacteremia, fulminant, coagulopathy markers in, 643
 - pneumonia, case reviews for 25-year period, 87
 - resistance in, in 1997, 212
 - vaccination
 - in college students, 648
 - in transplantation, 857

- Neisseria subflava* infections, meningitis, 615
- Nelfinavir, for HIV infection, S160
- adverse effects, S96
 - in drug combinations, S123, S160
 - pharmacodynamics, S151
- Neonatal infections
- candidiasis, practice guidelines, 662
 - due to herpes simplex virus, vaccination, 549
 - due to streptococci group B, invasive, surveillance for, 276
- Nephrolithiasis, due to antiretroviral agents, S96
- Neuroborreliosis, treatment [letter], 237, 410
- Neurologic disorders
- due to antiretroviral agents, S96
 - in enterovirus 71 infections, treatment [letter], 988
 - in herpes simplex virus infections, vaccination, 549
 - in HIV infection, vs. cerebrospinal fluid viral load, 962
 - in malaria, causes [letter], 836
 - in tuberculosis, 915
- Neurosyphilis, in HIV infection, treatment, 540
- Neutropenia
- antifungal prophylaxis in, 300
 - due to antiretroviral agents, S96
 - in bone marrow transplantation, *Stentotrophomonas maltophilia* infections in, 195
 - candidiasis prophylaxis in, practice guidelines, 662
 - fever in, treatment, with quinolones, 243
 - in HIV infection, 256
 - zygomycosis in, 851
- Neutrophil(s), dysfunction, in HIV infection, 256
- Nevirapine, for HIV infection
- adverse effects, S96
 - in drug combinations, S123, S130
 - resistance to, S185
- Nose, pressures within, during blowing, sneezing, and coughing, sinusitis and, 387
- Nosocomial infections (see also Catheter-related infections)
- due to *Aspergillus* [letter], 984
 - bacteremia
 - contaminants vs. true pathogens in [letter], 986
 - due to *Staphylococcus aureus* infections, methicillin-resistant, pathogenic significance, 368
 - control, hand disinfection in [letter], 990
 - due to *Enterobacter cloacae*, 35
 - epidemiology, in rehabilitation unit, 425
 - due to hepatitis C virus, in health care workers, May News and Events
 - due to *Klebsiella pneumoniae*, 55
 - meningitis, due to *Rhodococcus equi*, treatment, 223
 - Mycobacterium bovis* infections, from chemotherapy solution contamination, 356
 - ocular, in bacteremia, 306
 - sporotrichosis, 255, 380
 - urinary, due to fungi, 14
 - zygomycosis, in cancer center, 851
- Nystatin, for candidiasis, practice guidelines, 662
- Oat bran, for diarrhea, protease inhibitor-associated, 908
- Occupational exposures, to opportunistic infections, prophylaxis, S29
- Ocular lesions (see Eye infections)
- Ofloxacin
- for *Escherichia coli* infections, adverse effects, 395
 - state-of-the-art, 243
- Ommaya reservoir, *Coccidioides immitis* hyphal forms in, 349
- Onychomycosis, due to *Candida*, practice guidelines, 662
- Opportunistic infections, in HIV infection (see also specific diseases)
- epidemiology, S5
 - prevention
 - adherence to, S15
 - adverse effects, S15
 - Bartonella*, S29
 - behavioral modifications in, S15
 - cost issues in, S15
 - discontinuation, S66
 - fungal, S1, S29
 - practice guidelines, S15, S29
 - hepatitis A, S15, S29
 - hepatitis B, S15, S29
 - hepatitis C, S1, S29, S77
 - human herpesvirus 8, S72
 - interactions in, S15
 - Mycobacterium avium* complex, S1, S15, S29, S66
 - in pediatric patients, S15
 - performance measures, S85
 - Pneumocystis carinii*, S1, S15, S29, S66
 - in pregnancy, S15, S29
 - respiratory, S1
 - Salmonella*, S29
 - Streptococcus pneumoniae*, S29
 - toxoplasmosis, S29, 602
 - tuberculosis, S1, S29
 - viral, S1
- Oral infections
- due to *Candida*, practice guidelines, 662
 - due to herpes simplex virus, vaccination, 549
- Oral vaccination, tuberculosis, purified protein derivative hypersensitivity response to, S217
- Osteomyelitis
- due to *Aspergillus*, practice guidelines, 696
 - due to *Candida*, practice guidelines, 662
 - due to *Sporothrix schenckii*, practice guidelines, 684
 - due to *Staphylococcus aureus*, treatment with ceftriaxone, 205
- Otitis media, due to *Streptococcus pneumoniae*, serogroups in, vaccine implications, 122
- Outbreaks
- Coccidioides immitis* infections, in returned travelers, 61
 - dengue fever, March News and Events
 - Klebsiella pneumoniae* infections, multidrug-resistant, 55
 - prediction, satellite technology in, April News and Events
 - Q fever, 214
 - Streptococcus pneumoniae* infections, serotype 1, 319
 - West Nile virus infections, 413
- Pancreatitis
- due to antiretroviral agents, S96
 - due to *Candida*, practice guidelines, 662
- Pancrelipase, for diarrhea, protease inhibitor-associated, 908
- Parainfluenza virus infections
- immunorestitution disease in, 882
 - vaccination, in transplantation, 857
- Paranasal sinusitis (see Sinusitis)
- Parapharyngeal abscess, in cat-scratch disease, 599
- Paraspinal abscess, due to *Peptostreptococcus micros*, 622
- Paronychia, due to *Candida* practice guidelines, 662
- Parotid gland, lymphoepithelial lesions, in HIV infection, malignant transformation, 947
- Parvovirus B19 infections, Raynaud's phenomenon in, 500

Pediatric patients

- GB virus C/hepatitis G virus infections in, epidemiology, 569
- Giardia lamblia* carriage in, 419
- hepatitis C in, treatment, 585
- human immunodeficiency virus infection in
 - opportunistic infection prophylaxis in, S15, S29, S85
 - rabies vaccination in, 218
 - treatment, adherence to, S171
- malnutrition in, cytomegalovirus infections in [letter], 408
- Staphylococcus aureus* infections in, methicillin-resistant, clonal features, 630
- streptococcal infections, group B, recurrent, in twins, 282
- streptococci group B infections in, invasive, surveillance for, 276
- Streptococcus pneumoniae* colonization in, 191
- Streptococcus pneumoniae* pneumonia in, influenza impact on, 784
- transplantation in, vaccination in, 857

Penicillin(s)

- for *Neisseria meningitidis* pneumonia, case reviews for 25-year period, 87
- for neurosyphilis, in HIV infection, 540
- resistance to, *Streptococcus pneumoniae*, 78, 520
 - in colonized infants, 191
 - surveillance for, 454
- for syphilitic uveitis, 479

Pentamidine, prophylactic, for opportunistic infections, S25, S29

Peptostreptococcus micros infections, paraspinal abscess, 622

Pericarditis

- due to *Aspergillus*, practice guidelines, 696
- due to *Candida*, practice guidelines, 662
- due to *Histoplasma capsulatum*, practice guidelines, 688

Peripheral neuropathy, due to antiretroviral agents, S96

Peritonitis

- due to *Aspergillus*, practice guidelines, 696
- due to *Candida*, practice guidelines, 662
- due to *Coccidioides immitis*, 971
- due to herpes simplex virus [letter], 839

Pertussis

- cough in, in military population, 387
- treatment, with erythromycin, February News and Events vaccination
 - applications to tuberculosis vaccination, S302
 - in transplantation, 857

Pharyngitis, due to herpes simplex virus, vaccination, 549

Phlebitis, due to *Candida*, practice guidelines, 662

Plague

- cat-associated, 893
- vaccination, 843

Plasmodium falciparum malaria, aspergillosis with, 938, 940Platelet count, in fulminant *Neisseria meningitidis* infections, 643

Pleural effusion, in voluntary cough suppression, 572

Pleural infections, due to *Aspergillus*, practice guidelines, 696

Pneumocephalus, due to fungi, 215

Pneumococcal infections (see *Streptococcus pneumoniae* infections)*Pneumocystis carinii* infections

- in HIV infection
 - central nervous system, treatment, 397
 - diagnosis, 141
 - prophylaxis, S1, S15, S29, S66
- immunorestitution disease in, 882
- sudden infant death syndrome in [letter], 991

Pneumonia

- due to *Aspergillus*, in malaria, 938
- due to *Blastomyces dermatitidis*, practice guidelines, 679

due to *Candida*, treatment, practice guidelines, 662

due to *Coccidioides immitis*, practice guidelines, 658

due to combined cytomegalovirus and *Bordetella bronchiseptica*, in malnutrition [letter], 408

due to *Coxiella burnetii*, 214

due to *Cryptococcus neoformans*, practice guidelines, 710

due to *Haemophilus influenzae*, in HIV infection, 461

due to *Legionella dumoffii*, organism detection in, 382

due to *Mycobacterium kansasii*, in cancer, 965

due to *Neisseria meningitidis*, case reviews for 25-year period, 87

due to *Pneumocystis carinii*, in HIV infection, diagnosis, 141

due to rhinovirus, 611

due to *Sporothrix schenckii*, practice guidelines, 684

due to *Staphylococcus aureus*, methicillin-resistant, in liver transplantation, 322

due to *Streptococcus intermedius*, with brain involvement, 396

due to *Streptococcus pneumoniae*

Fc,RIIIa-R131 allotype and, 25

influenza impact on, 784

penicillin-resistant, outcome, 520

serogroups vs. disease severity and manifestations, vaccine implications, 100, 122

treatment [letter and reply], 234

treatment, with quinolones, 243

viral, immunorestitution disease in, 882

Poliomyelitis, vaccination, in transplantation, 857

Polymerase chain reaction

for *Chlamydia trachomatis*, in screening program [letter and reply], 406

for herpes simplex virus, in meningitis, 176

for *Legionella dumoffii*, 382

for *Mycobacterium bovis*, in contaminated chemotherapy solutions, 356

for *Pneumocystis carinii*, in HIV infection, 141

Portosystemic shunts, bacteremia due to, 384

Potassium iodide solution, for sporotrichosis, 684

Practice guidelines (see Infectious Diseases Society of America, practice guidelines)

Pregnancy

chloramphenicol use in [letter], 237

herpes simplex virus infections in, type 2, amniotic fluid viral load in, 363

histoplasmosis in, practice guidelines, 688

HIV infection in, opportunistic infection prophylaxis in, S15

streptococci group B infections in, invasive, surveillance for, 276

Prescription drugs, direct-to-consumer advertising, June News and Events

Prevotella, vaginal colonization, variation with menstrual cycle, 901

Progressive multifocal leukoencephalopathy

in HIV infection

brain biopsy in, 491

treatment, 95

treatment [letter], 234

Prophylaxis

Bartonella infections, in HIV infection, S29

candidiasis

in HIV infection, S29

practice guidelines, 662

coccidioidomycosis, in HIV infection, S29

cryptococcosis, in HIV infection, S29

cryptosporidiosis, in HIV infection, S29

cytomegalovirus infections, in HIV infection, S1, S15, S29

foodborne diseases, in HIV infection, S29

- fungal infections
 in HIV infection, S1, S15
 in neutropenia, 300
 gastrointestinal infections, in HIV infection, S29
 hepatitis A, in HIV infection, S15, S29
 hepatitis B, in HIV infection, S15, S29
 hepatitis C, in HIV infection, S1, S29
 herpes simplex virus infections, in HIV infection, S1, S29
 histoplasmosis, in HIV infection, S29
 human herpesvirus 8 infections, in HIV infection, S1
 human papillomavirus infections, in HIV infection, S29
 influenza
 in HIV infection, S15, S29
 zanamivir for, 587
 Kaposi's sarcoma, in HIV infection, S1
 lymphoma, in HIV infection, 757, 762
Mycobacterium avium complex infections, in HIV infection, S1, S15, S29, S66
 opportunistic infections in HIV infection (*see* Opportunistic infections, in HIV infection, prevention)
Pneumocystis carinii infections, in HIV infection, S1, S15, S29, S66
 respiratory infections, in HIV infection, S1, S15, S29
Salmonella infections, in HIV infection, S29
 sexually transmitted diseases, in HIV infection, S29
Streptococcus pneumoniae infections, in HIV infection, S15, S29
 toxoplasmosis, in HIV infection, S29, 602
 travelers' diseases, in HIV infection, S29
 tuberculosis, in HIV infection, S29
 varicella-zoster infections, in HIV infection, S1, S29
 waterborne diseases, in HIV infection, S29
Propionibacterium acnes infections
 endocarditis, in liver transplantation, 224
 hepatic granuloma, 219
 Prostatitis, due to *Histoplasma capsulatum*, 595
 Prosthetic valve infections, due to *Mycobacterium fortuitum*, treatment, 629
 Protease inhibitors, for HIV infection (*see also specific drugs*)
 adverse effects, S96, S135, S160
 clinical studies, S160
 in drug combinations, S160
 drug regimens sparing, S130
 failure, S160
 pharmacodynamics, S151
 research on, S160
 Protozoan infections, nonpathogenic, reporting practice guidelines for, 401
Pseudallescheria boydii infections, meningitis, treatment with voriconazole, 981
Pseudomonas aeruginosa infections
 bacteremia, antibiotic susceptibility surveillance, 454
 endocarditis, in injection drug users, 374
 in rehabilitation unit, 425
 resistance in, 454
 Pseudotumor, inflammatory, in HIV infection, treatment with thalidomide, 826
 Psychiatric disorders, due to metronidazole, 213
 Psyllium, for diarrhea, protease inhibitor-associated, 908
 Purified protein derivative, delayed hypersensitivity to, mucosal bacille Calmette-Guérin effects on, S217
 Pyrazinamide, prophylactic, for opportunistic infections, S25
 Pymethamine, prophylactic, for opportunistic infections, S25, S29
 Q fever
 endocarditis in, *Bartonella* cross-reactivity in, 609
 outbreaks, 214
 vaccination, 843
 QT interval, June News and Events
 Quinolones
 new, March News and Events
 prophylactic, for opportunistic infections, S29
 resistance to, 454
 state-of-the-art, 243
 Quinupristin/dalfopristin, for *Enterococcus faecium* infections
 failure, 403
 vancomycin-resistant, 790
 Rabbit fever (*see* Tularemia)
 Rabies
 state-of-the-art, 4
 vaccination
 in HIV infection, 218
 in transplantation, 857
 Radial artery harvest site, infections, risk factors for, 270
 Radiculomyelitis, in tuberculosis, 915
 Ranitidine, for *Helicobacter pylori* infections, serologic evaluation after, 976
 Raynaud's phenomenon, in parvovirus B19 infections, 500
 Rehabilitation, nosocomial infections in, epidemiology, 425
 Resistance (*see* Drug resistance)
 Respiratory failure, in histoplasmosis, in HIV infection, 877
 Respiratory infections (*see also* Pneumonia; Tuberculosis)
 due to *Aspergillus*
 in malaria, 938, 940
 in multiple myeloma, 41
 practice guidelines, 696
 due to *Blastomyces dermatitidis*, practice guidelines, 679
 due to *Coccidioides immitis*
 outbreak in returned travelers, 61
 practice guidelines, 658
 due to *Coxiella burnetii*, 214
 due to *Cryptococcus neoformans*, practice guidelines, 710
 due to *Histoplasma capsulatum*, practice guidelines, 688
 in HIV infection, prophylaxis, S1, S15, S29
 due to *Leishmania donovani*, 764
 in military forces, causes, 534
 due to *Mycobacterium avium* complex
 treatment with clarithromycin-including regimens, 288
 in voluntary cough suppression, 572
 due to *Mycobacterium bovis*, from chemotherapy solution contamination, 356
 due to *Mycobacterium kansasii*, in cancer, 965
 due to *Mycobacterium terrae*, 444
 due to *Sporothrix schenckii*, practice guidelines, 684
 treatment, with quinolones, 243
 Respiratory syncytial virus infections, vaccination, in transplantation, 857
 Retinal lesions, in bacteremia, 306
 Retinitis
 due to cytomegalovirus, in HIV infection, 182
 due to *Treponema pallidum*, 479
 Reverse-transcriptase inhibitors
 nucleoside, for HIV infection (*see also specific drugs*)
 adverse effects, S96
 protease inhibitors with, S160

- resistance to, S185
 - nucleoside, for HIV infection (*see also specific drugs*)
 - adverse effects, S96
 - hydroxyurea with, S193
 - protease inhibitors with, S160
 - resistance to, S185
- Rheumatic disease, in parvovirus B19 infections, 500
- Rhinovirus infections, pneumonia, 611
- Rhodococcus equi* infections, meningitis, treatment, 223
- Rhodotorula rubra* infections, prophylaxis, in neutropenia, 300
- Ribavirin, for hepatitis C, in pediatric patients, 585
- Ricin toxin, vaccination, 843
- Rifabutin
 - for *Mycobacterium avium* complex infections, 288
 - prophylactic, for opportunistic infections, S25, S29
 - for tuberculosis, in HIV infection, 779
- Rifalizil, for tuberculosis, animal model, S288
- Rifampin, prophylactic, for opportunistic infections, S25, S29
- Ritonavir, for HIV infection, S160
 - adverse effects, S96, S135
 - in drug combinations, S123, S160
 - pharmacodynamics, S151
 - resistance to, S185
- Rotavirus infections
 - diarrhea
 - in Swedish adults, 770
 - vaccination, in transplantation, 857
- Roth's spots, in bacteremia, 306
- Rubella, vaccination, in transplantation, 857
- Saksenaea vasiformis* infections, mucormycosis, 942
- Salmonella* infections
 - diarrhea
 - in Swedish adults, 770
 - in HIV infection, prophylaxis, S29
 - nontyphoid, bacteremia, age-related differences [letter and reply], 239
- Salmonella typhimurium* infections, brain abscess, 621
- Saquinavir, for HIV infection, S160
 - adverse effects, S96, S135
 - in drug combinations, S123, S160
 - pharmacodynamics, S151
- Satellite technology, in outbreak prediction, April News and Events
- Scopulariopsis brevicaulis* infections, subcutaneous, in liver transplantation, 820
- Semmelweis principles, of hand disinfection [letter], 990
- SENTRY Antimicrobial Surveillance Program, results for 1997 and 1998, 454
- Septic arthritis
 - due to *Candida*, practice guidelines, 662
 - due to *Clostridium*, 590
- Septic shock, in *Saksenaea vasiformis* infections, 942
- Septicemia (*see* Bacteremia)
- Sexually transmitted diseases (*see also specific diseases*)
 - in HIV infection, prophylaxis, S29
 - in military
 - chlamydial infections, 742
 - gonorrhea, 742
 - historical background, 719
 - prevention of, 730
 - risk behavior and, 723, 730
 - urethritis in, 736
 - susceptibility to, menstrual cycle and, 901
 - treatment, with quinolones, 243
- Shiga toxin-producing *Escherichia coli* infections, urinary tract, hemolytic-uremic syndrome in, 395
- Shigella* infections
 - diarrhea
 - in Swedish adults, 770
 - resistance in, S15
- Shock
 - in histoplasmosis, in HIV infection, 877
 - septic, in *Saksenaea vasiformis* infections, 942
- Shunts
 - portosystemic, bacteremia due to, 384
 - ventriculoperitoneal, *Coccidioides immitis* hyphal forms in, 349
- Sinusitis
 - due to *Aspergillus*
 - in multiple myeloma, 41
 - practice guidelines, 696
 - due to fungi, pneumocephalus in, 215
 - nose blowing impact on, 387
 - treatment, with quinolones, 243
- Skin lesions
 - due to *Alternaria*, 13, 174
 - due to antiretroviral agents, S96
 - due to *Aspergillus*, practice guidelines, 696
 - due to *Candida*, practice guidelines, 662
 - due to combined cytomegalovirus and *Bordetella bronchiseptica*, in malnutrition [letter], 408
 - due to herpes simplex virus, vaccination, 549
 - in HIV infection, primary, in African women, 486
 - larva migrans, treatment, 811
 - due to *Mycobacterium bovis*, from chemotherapy solution contamination, 356
 - due to *Leishmania*, epidemiology, East Timor [letter], 840
 - due to nontuberculous mycobacteria, 29
 - due to *Scopulariopsis brevicaulis*, in liver transplantation, 820
 - due to *Sporothrix schenckii*, 255, 380
 - in Peru, 65
 - practice guidelines, 684
 - treatment, with quinolones, 243
 - in tuberculosis, 201
 - in West Nile virus infections, 413
- Skin tests, for *Coccidioides immitis*, in California, 612
- Sleep disorders, due to antiretroviral agents, S96
- Smallpox vaccination, as bioterrorism protection, 843, May News and Events
- Soft-tissue infections (*see also* Cellulitis)
 - due to *Clostridium difficile*, 954
 - due to *Haemophilus aphrophilus*, 627
 - due to *Scopulariopsis brevicaulis*, in liver transplantation, 820
 - treatment, with quinolones, 243
- SP-303, for diarrhea, protease inhibitor-associated, 908
- Sparfloxacin
 - state-of-the-art, 243
 - for *Streptococcus pneumoniae* pneumonia [letter and reply], 234
- Specialists, in infectious diseases, impact [letter and reply], 838
- Spinal cord
 - herpes simplex virus infections, vaccination, 549
 - injury, rehabilitation, nosocomial infection epidemiology in, 425
 - Mycoplasma pneumoniae* infections, organism detection in [letter and reply], 405
 - tuberculosis manifestations in, 915
- Spine
 - abscess, due to *Peptostreptococcus micros*, 622

- echinococcal cyst, 442, 567
- Splenomegaly, in HIV infection, 943
- Sporotrichosis
 - diagnosis, 255, 380
 - epidemiology, Peru, 65
 - practice guidelines, 684
- Staphylococcal enterotoxin B, vaccination, 843
- Staphylococcal infections
 - coagulase-negative, bacteremia, antibiotic susceptibility surveillance, 454
 - endocarditis, in bicuspid aortic valve, 336
- Staphylococcus aureus* infections
 - aortic aneurysm in, in dialysis, 823
 - bacteremia
 - antibiotic susceptibility surveillance, 454
 - database on, 633
 - after portosystemic shunt placement, 384
 - endocarditis, in injection drug users, 374
 - liver abscess, in chronic granulomatous disease, treatment with granulocyte-macrophage colony-stimulating factor, 222
 - methicillin-resistant
 - bacteremia, pathogenic significance, 368
 - clonal features, 630
 - in liver transplantation, 322
 - in rehabilitation unit, 425
 - surveillance for, 454
 - susceptibility testing, 799
 - treatment, with linezolid, 146
 - osteomyelitis, treatment with ceftriaxone, 205
 - resistance in, vancomycin, susceptibility testing, 799
 - virulence factors, in endocarditis, 374
- Stavudine, for HIV infection
 - adverse effects, S96
 - in drug combinations, S123, S143
 - hydroxyurea with, S193
 - lactic acidosis due to, 198
 - resistance to, S185
- Stem cells, transplantation, influenza vaccination in, granulocyte-macrophage colony-stimulating factor with, 342
- Stentrophomonas maltophilia* infections, bacteremia, in bone marrow transplantation, 195
- Stereotactic biopsy, brain lesions, in HIV infection, 491
- Stevens-Johnson syndrome, due to antiretroviral agents, S96
- Streptococcal infections
 - endocarditis, in bicuspid aortic valve, 336
 - group B
 - invasive, maternal and neonatal, surveillance for, 276
 - recurrent, in twin infants, 282
 - β -hemolytic, endocarditis, mortality in, 624
 - susceptibility testing, 799
 - toxic shock syndrome in
 - kallikrein-kinin system activation in, 961
 - physician's personal experience, 922
 - viridans
 - endocarditis, in bicuspid aortic valve, 336
 - meningitis [letter and reply], 238
- Streptococcus agalactiae* infections
 - invasive, maternal and neonatal, surveillance for, 276
 - recurrent, in twin infants, 282
- Streptococcus intermedius* infections, pneumonia, with brain involvement, 396
- Streptococcus pneumoniae*
 - colonization, penicillin-resistant, 191
 - susceptibility testing, 799
- Streptococcus pneumoniae* infections
 - bacteremia, antibiotic susceptibility surveillance, 454
 - in HIV infection, prophylaxis, S15, S29
 - meningitis, 71
 - pneumonia
 - Fc, RIIIa-R131 allotype and, 25
 - influenza impact on, 784
 - treatment [letter and reply], 234
 - resistance in, 71, 520
 - serogroups
 - vs. disease severity and manifestations, vaccine implications, 100, 122
 - outbreak of type 1, 319
 - vaccination, 319
 - education on, April News and Events
 - in military, 157
 - in transplantation, 857
 - trial design, S206
- Streptomycin, resistance to, *Shigella*, 515
- Strongyloidiasis, in HIV infection, epidemiology [letter], 241
- Sudden infant death syndrome, due to *Pneumocystis carinii* [letter], 991
- Sulfadiazine, prophylactic, for opportunistic infections, S29
- Sulfisoxazole, resistance to, *Shigella*, 515
- Surgical infections
 - epidemiology, in rehabilitation unit, 425
 - meningitis, diagnosis [letter and reply], 836
 - radial artery harvest site, risk factors for, 270
- Surveillance
 - antibiotic susceptibility, 454
 - funguria, 14
 - group B streptococcal infections, maternal and neonatal, 276
 - outbreak potential, satellite technology in, April News and Events
 - West Nile virus, May News and Events
- Susceptibility testing (see also Drug resistance)
 - Bacteroides*, 870
 - fastidious organisms, 799
 - Mycobacterium terrae*, 444
 - SENTRY surveillance program, 454
- Sweet's syndrome, in mycobacterial infections, 29
- Syphilis
 - in HIV infection, treatment, 540
 - uveitis in, 479
- Tenosynovitis, due to *Mycobacterium terrae* 444
- Terbinafine
 - for *Scopulariopsis brevicaulis* infections, in liver transplantation, 820
 - for sporotrichosis, 684
- Terconazole, for candidiasis, practice guidelines, 662
- Terrorism (see Bioterrorism)
- Tetanus, vaccination, in transplantation, 857
- Tetracycline, resistance to, *Shigella*, 515
- Thalidomide, for inflammatory pseudotumor, in HIV infection, 826
- Thiabendazole, for cutaneous larva migrans, 811
- Thrombopoietin, measurement, in fulminant *Neisseria meningitidis* infections, 643
- Tick-borne encephalitis, isolated initial phase [letter], 987
- Tioconazole, for candidiasis, practice guidelines, 662
- Tipranavir, for HIV infection, S160
- T lymphocytes
 - bacille Calmette-Guérin response, S257

- in HIV infection (*see* Human immunodeficiency virus infection, T lymphocytes in)
- Mycobacterium tuberculosis* ESAT-6 antigen response, S201
- Mycobacterium tuberculosis* response, S257
- Tobramycin, extended-interval dosing, national survey, 433, 440
- Tonate virus infections, encephalitis, 188
- Toxic shock syndrome, streptococcal
 - kallikrein-kinin system activation in, 961
 - physician's personal experience, 922
- Toxoplasmosis, in HIV infection, prophylaxis, S15, S29, 602
- Tracheitis, due to *Aspergillus*, practice guidelines, 696
- Tracheobronchitis, due to *Aspergillus*, in malaria, 938
- Transjugular intrahepatic portosystemic shunt, bacteremia due to, 384
- Transplantation
 - bone marrow, *Stentotrophomonas maltophilia* bacteremia in, 195
 - candidiasis prophylaxis in, practice guidelines, 662
 - heart, *Mycobacterium avium* complex intestinal infections in, 603
 - immunorestitution disease in, 882
 - kidney, lymphoma after, Epstein-Barr virus detection in, 576
 - liver
 - Propionibacterium acnes* endocarditis in, 224
 - Scopulariopsis brevicaulis* infections in, 820
 - Staphylococcus aureus* infections in, methicillin-resistant, 322
 - stem cell, influenza vaccination in, granulocyte-macrophage colony-stimulating factor with, 342
 - vaccination in, in pediatric patients, 857
- Transverse myelitis, due to *Mycoplasma pneumoniae*, organism detection in [letter and reply], 405
- Travelers' diseases
 - African trypanosomiasis, case study [letter], 985
 - due to *Coccidioides immitis*, 61
 - due to *Coxiella burnetii*, 214
 - cutaneous larva migrans, treatment, 811
 - in HIV infection, prophylaxis, S29
 - importance, 809
 - interdisciplinary management, 809
 - multidrug-resistant tuberculosis, 617
 - vaccination, in transplantation, 857
- Treponema pallidum* infections, uveitis in, 479
- Triglycerides, elevation, due to antiretroviral agents, S96
- Trimethoprim-sulfamethoxazole
 - prophylactic, for opportunistic infections, S25, S29
 - resistance to, *Shigella*, 515
- Trovaflaxacin
 - hepatitis due to, 400
 - state-of-the-art, 243
- Trypanosomiasis, African, case study [letter], 985
- Tuberculoma, cerebral, treatment, 625
- Tuberculosis
 - asymptomatic, diagnosis, S243
 - atypical presentations, population-based survey, 293
 - aural, treatment, paradoxical reaction in, 625
 - diagnosis
 - immunologic, S243
 - in vaccination trial design, S230, S276
 - epidemics, control with vaccines, S316
 - epidemiology, S233
 - in HIV infection
 - prophylaxis, S1, S15, S29
 - treatment with rifabutin, 779
 - immunity to, correlates, S279
 - immunorestitution disease in, 882
 - latent, practice guidelines for, February News and Events
 - lumbarosacral plexopathy in, 116
 - miliary, cutaneous manifestations, 201
 - radiculomyelitis in, 915
 - research on, S233
 - resistance in, multiple, 617
 - screening for, in sexually transmitted disease clinics [letter], 986
 - symptoms, population-based survey, 293
 - transmission, multidrug-resistant strain, 617
 - treatment, with rifalazil and isoniazid, S288
 - vaccination
 - adjuvants in, S266
 - DNA vaccines in, S233, S247, S283
 - efficacy
 - aerosol challenge, S299
 - evaluation procedures for, S250, S257, S262, S276
 - in epidemic control, S316
 - ESAT-6 antigen and, S201
 - geographical effects on, S262
 - historical background, S262
 - in HIV infection, S309
 - ideal vaccine for, S233
 - immunologic diagnosis before, S243
 - mouse models, S283
 - mucosal, S217
 - Mycobacterium bovis* antigen MPB83 in, S283
 - Mycobacterium bovis* infection vs. bacille Calmette-Guérin, S291
 - Mycobacterium vaccae* in, S309
 - national developmental strategy for, S233
 - new products for, S254
 - pertussis vaccination experience and, S302
 - pneumonia vaccine information applied to, S206
 - primate model for, S210
 - protective immunity correlates, S279
 - regulatory procedures for, S247
 - trials, S213
 - clinical considerations in, S230
 - ethical issues in, S266
 - veterinary, S222, S283, S291
- Tularemia
 - ataxia in, 211
 - endocarditis in, 399
 - organism detection in, 166
 - vaccination, 843
- Ultrase MT 20, for diarrhea, protease inhibitor-associated, 908
- United States Public Health Service, opportunistic infection prevention practice guidelines (*see* Opportunistic infections, in HIV infection, prevention)
- Ureaplasma urealyticum* infections, in military, 736
- Urethritis
 - due to herpes simplex virus, screening for, 982
 - in military, 736
- Urinary tract infections
 - due to *Aspergillus*, practice guidelines, 696
 - due to *Candida*, practice guidelines, 662
 - epidemiology, in rehabilitation unit, 425
 - due to *Escherichia coli*, Shiga toxin-producing, hemolytic-uremic syndrome in, 395
 - due to fungi, surveillance, 14
 - recurrent, in postmenopausal women, 152
 - treatment, with quinolones, 243
- Urine

- Legionella dumoffii* detection in, 382
retention of, recurrent infections in, 152
Uveitis, due to *Treponema pallidum*, 479
- Vaccines and vaccination
adjuvants for, S266
anthrax, 843
bacille Calmette-Guérin (see Bacille Calmette-Guérin, vaccination with)
for bioterrorism, 843
botulism, 843
Brucella, 843
Coxiella burnetii, 843
cytomegalovirus, in transplantation, 857
diphtheria, in transplantation, 857
Epstein-Barr virus, in transplantation, 857
Haemophilus influenzae
in transplantation, 857
trial design, S206
hepatitis A, in transplantation, 857
hepatitis B, in transplantation, 857
herpes simplex virus
review article, 549
in transplantation, 857
in HIV infection, for opportunistic infections, S15
influenza
in stem cell transplantation, granulocyte-macrophage colony-stimulating factor with, 342
in transplantation, 857
Lyme disease, May News and Events
in transplantation, 857
measles, in transplantation, 857
mumps, in transplantation, 857
Neisseria meningitidis
in college students, 648
in transplantation, 857
parainfluenza virus, in transplantation, 857
pertussis
applications to tuberculosis vaccination, S302
in transplantation, 857
plague, 843
poliomyelitis, in transplantation, 857
Q fever, 843
rabies, 4
in HIV infection, 218
in transplantation, 857
respiratory syncytial virus, in transplantation, 857
ricin toxin, 843
rotavirus, in transplantation, 857
rubella, in transplantation, 857
smallpox, May News and Events, 843
staphylococcal enterotoxin B, 843
Streptococcus pneumoniae, 319
education on, April News and Events
in military, 157
serogroup considerations, 100, 122
in transplantation, 857
trial design, S206
tetanus, in transplantation, 857
in transplantation, in pediatric patients, 857
travelers' diseases, in transplantation, 857
tuberculosis (see Tuberculosis, vaccination)
tularemia, 843
varicella-zoster virus, in transplantation, 857
Venezuelan equine encephalitis, 843
- Vagina
candidiasis, in primary HIV infection, in African women, 486
microflora, menstrual cycle variations in, 901
Varicellazoster virus, prophylactic, for opportunistic infections, S29
Vancomycin
resistance to (see Enterococcal infections, vancomycin-resistant)
Staphylococcus aureus, 799
for *Streptococcus pneumoniae* infections, cefotaxime-resistant, 71
Varicella-zoster virus infections
facial nerve palsy in, 529
in HIV infection, prophylaxis, S1, S29
vaccination, in transplantation, 857
Vasculitis, in parvovirus B19 infections, 500
Venezuelan equine encephalitis
tonate virus subtype of, 188
vaccination, 843
Ventriculoperitoneal shunts, *Coccidioides immitis* hyphal forms in, 349
Viridans streptococcal infections
endocarditis, in bicuspid aortic valve, 336
meningitis [letter and reply], 238
Virulence factors, *Streptococcus pneumoniae*, Fc,RIIIa-R131 allo-types and, 25
Visceral leishmaniasis, natural history, in Brazil, 608
Voriconazole, for *Pseudallescheria boydii* meningitis, treatment with voriconazole, 981
- Waterborne diseases
due to *Escherichia coli*, hemolytic-uremic syndrome in [letter and reply], 984
in HIV infection, prophylaxis, S29
Weakness, in West Nile virus infections, 413
Weight loss
in histoplasmosis, 595
in tuberculosis, population-based survey, 293
West Nile virus infections
mosquito control in, May News and Events
outbreaks, 413
White, Arthur C., memorial to, 3
Whooping cough (see Pertussis)
- Yersinia pestis* infections
cat-associated, 893
vaccination, 843
- Zalcitabine, for HIV infection
adverse effects, S96
in drug combinations, S123
hydroxyurea with, S193
Zanamivir, for influenza, prophylactic, 587
Zidovudine, for HIV infection
adverse effects, S96
in drug combinations, S123, S130, S160
hydroxyurea with, S193
resistance to, S185
Zygomycosis, in cancer center, 851